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Infectious agents that induce cross-reactive myocarditic T cell responses may cause autoimmune 
inflammation of the heart, dilated cardiomyopathy (DCM), and heart failure.  The purpose of this 
study was to evaluate the efficacy of GMCSF-Myosin fusion proteins as tolerogenic vaccines 
capable of inhibiting experimental autoimmune myocarditis (EAM).  The fusion proteins were 
comprised of an N-terminal granulocyte macrophage-colony stimulating factor (GM-CSF) 
domain and a C-terminal cardiac myosin antigen domain. The antigenic domains Myosin 1052-
1076 and Myosin 614-643 were chosen based on epitopes known to cause EAM in Lewis rats 
and BALB/c mice, respectively.  Bioactivity of the cytokine domains for GMCSF-Myo1052 and 
GMCSF-Myo614 were confirmed with bone marrow proliferation assays.  Enhanced antigen 
presentation was confirmed for GMCSF-Myo1052.  Both fusion proteins were found to inhibit 
disease progression when given as a pretreatment before EAM induction.  When administered 
after disease induction, GMCSF-Myo614 reduced the incidence of EAM.  To investigate the 
mechanisms of these tolerogenic vaccines, a model of EAM was developed in C57BL/6 mice by 
evaluating a peptide (myosin 718-736) derived from the murine cardiac alpha myosin heavy 
chain and theorized to bind to H2-I-A
b





) mice on the C57BL/6 background.  Defining the mechanisms by 
which Interferon-gamma (IFN-γ) inhibits EAM on the C57BL/6 background is beyond the scope 
of this project, but it is hypothesized that T cell apoptosis or induction of T regulatory cells is 
involved.  In conclusion, this study demonstrated the feasibility of using GMCSF-Myosin fusion 
proteins to inhibit EAM, and provides a new model of EAM on C57BL/6 background to explore 
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1.1 A PRIMER ON MYOCARDITIS 
 
Myocarditis is defined as inflammation of cardiac tissue including the walls of the 
ventricles, valves, chordae tendineae and papillary muscle.  The severity of the disease can range 
from subclinical to life threatening.  Multiple viruses are known to directly infect the heart 
causing acute myocarditis.   Often the immune system can resolve viral cardiac infection.  
However, it is also possible an acute infection can lead to auto-reactive lymphocytes if the 
infection is not resolved by the innate immune system.  Cardiac auto-reactive lymphocytes can 
also be generated during infections that do not directly infect the heart through molecular 
mimicry.  In either event, cardiac auto-reactive lymphocytes can lead to a specific type of 
myocarditis defined as autoimmune myocarditis.  This subtype of myocarditis is of significant 
concern because the heart itself provides a constant supply of cardiac antigens that keep the 
adaptive immune system in a perpetual cycle of inflammation.    
Identifying and stopping autoimmune myocarditis is of the upmost importance to prevent 
dilated cardiomyopathy.   Chronic as well severely acute cardiac inflammation can lead to 
myocyte death and subsequent scarring in place of the dead tissue.  Scarring of the ventricles can 
lead to decreased diastolic and systolic function.  If the impairment is severe enough, the heart 
may enlarge in attempt to compensate for the decreased cardiac output.  This enlargement of the 
heart is an inefficient solution that ultimate results in dilated cardiomyopathy where the walls of 
the ventricles become progressively thinner reducing cardiac output and function.  To prevent 
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autoimmune myocarditis from evolving into dilated cardiomyopathy and heart failure, diagnosis 
and novel treatments are needed. 
Diagnosis of myocarditis has been difficult due to the focal nature of the disease.   
Certain sections of the heart can become infected and/or inflamed while the rest of the heart 
tissue remains normal.  This focal characteristic of myocarditis creates problems when 
endomyocardial biopsies are performed because it is possible that a biopsy may miss an inflamed 
or infected region resulting in a false negative diagnosis.  To gain a better understanding of the 
true prevalence of the disease, several post mortem studies have been conducted where the entire 
heart can be removed and analyzed to minimize false negatives.  A review several post mortem 
studies found incidence rates from 1% to 10% [1]. However, 3 of these post mortem studies, in 
which 10,000 or more subjects were used, found incidence rates for myocarditis between 3.5% 
and 0.11%.  Furthermore, Japan had a lower incidence rate comparted to the United States, 
indicating environment and/or ethnicity may be contributing factors.  Histological analysis of 
endomyocardial biopsies has revealed that lymphocytic, eosinophilic, and giant cell myocarditis 
are the three main forms of myocarditis found in patients [2].  Lymphocytic myocarditis is the 
most common form of myocarditis with the most favorable prognosis [2].  Eosinophilic and giant 
cell myocarditis may progress rapidly, and both have a poor prognosis and high mortality rates 









1.2 CAUSES OF MYOCARDITIS 
 
Pathogenic origins of myocarditis 
While the cause of myocarditis in most cases is unconfirmed, known origins for 
myocarditis include pathogenic infection, autoimmune disease, genetic predisposition, and other 
factors.  Pathogenic infections are the most commonly diagnosed known causes of myocarditis.  
Practically every class of pathogen from viruses to parasites is known as a potential cause of 
myocarditis.  In North America and Europe, viral agents are the most common cause with 
adenoviruses and enteroviruses commonly implicated.   A 2010 study using endomyocardial 
biopsy found 38% of 624 patients with myocarditis had viral genomes present in their heart 
tissue [3].   Viruses can cause direct necrosis of cardiomyocytes and activate the adaptive 
immune system which can cause collateral damage during viral eradication.   
One of the most-well-studied bacteria capable of inducing myocarditis is beta hemolytic 
streptococcus.  Infection with this pathogen is aggressively treated with antibiotics to prevent the 
development of myocarditis.  Myocarditis following beta hemolytic strep is a well-documented 
condition called Rheumatic fever.  Molecular mimicry is implicated as antibodies against the 
coat protein of beta hemolytic strep also cross react with cardiac myosin [4].  A single cross 
reactive antibody in theory could opsonize heart tissue leading to the presentation of more 
cardiac epitopes which may activate naïve cardiac auto-reactive T cells leading to further cardiac 
damage and autoimmune myocarditis.  Antibiotics are commonly prescribed to help the innate 
immune system quickly clear the invading bacterial pathogen and abrogate the need for adaptive 
immunity to select and colonially expand lymphocytes, including B cells. 
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At the protozoan level Trypanosoma cruzi is the most common cause of myocarditis.  
The parasite is responsible for 1-7 million current infections in North America alone and 30% of 
these patients will develop myocarditis [5].  While some researchers believe Trypanosoma cruzi 
causes myocarditis by direct infection of cardiac tissue, other researchers argue that an 
autoimmune etiology better explains the current clinical literature.  Aspects that support an 
autoimmune etiology  include: parasite load not correlating with severity of myocarditis, 
multiple target organs are known to be infected by the parasite yet only the heart seems to 
display chronic inflammation, and Trypanosoma cruzi patients maybe asymptomatic for years 
before displaying signs of myocarditis [5].  Research has also identified antibodies that react to 
the P0 ribosomal antigen of Trypanosoma cruzi and cross-react with the second loop of the beta 
1 adrenergic receptor [6].  The beta 1 adrenergic receptor is expressed in cardiac tissue, and 
antibodies with agonist activity can easily overstimulate the heart and lead to cardiomyopathy.  
In addition to molecular mimicry at the B cell level, researchers have also discovered T cells that 
react to the B13 antigen of Trypanosoma cruzi and cardiac myosin [7]. 
 
HLA associations with myocarditis 
Because CD4
+
 T cells are the pivotal leukocyte that drives EAM and have been 
implicated in human autoimmune myocarditis, understanding which cardiac epitopes drive CD4
+
 
T cell expansion is critical for managing autoimmune myocarditis [8-11].  CD4
+
 T cells 
recognize peptide antigens when presented on MHC II surface molecules by antigen presenting 
cells (APCs).  Genes encoding the major histocompatibility complex, including HLA-DP, HLA-
DQ, and HLA-DR, are some of the most polymorphic genes in the human genome.  Each allele 
has the potential to bind a different peptide antigen derived from a protein.  Many T cells that 
bind too strongly to self-peptides in the context of MHC are eliminated during negative thymic 
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selection [12].  However, thymic elimination of T cells with substantial affinity for self-antigens 
is not perfect [13].  Evidence also shows the alpha myosin cardiac heavy chain is weakly 
expressed in the thymus of mice and possibly weakly expressed in the thymus of humans as well 
[14].  Therefore, it is possible cardiac auto-reactive T cells are commonly found in the periphery.  
Auto-reactive myosin specific T cells in the periphery are most likely controlled through antigen 
specific T regulatory cells.  Certain allelic versions of MHC II may have a higher affinity for 
peptides derived from the cardiac myosin heavy chain.  In theory, certain MHC II alleles, auto-
reactive CD4
+
 T cells, as well as other unknown genetic factors could contribute to autoimmune 
myocarditis.   
Multiple research studies have been conducted to explore the possible link between 
certain MHC II alleles and myocarditis as well as inflammatory idiopathic dilated 
cardiomyopathy (IDC).  A study in China found HLA-DQA1*0501 and HLA-DQB1*0303 were 
statistically associated with higher odds ratios for idiopathic dilated cardiomyopathy [15].  The 
same study also reported HLA-DQA1*0201 and DQB1*0502 were significantly lower in 
patients with IDC suggesting that these alleles may offer protection against IDC.  A subsequent 
study showed HLA-DQB1*0303 was associated with myocarditis, and HLA DQB1*02-
DQB1*03 was correlated with inflammatory infiltrates in patients with IDC [16]. While the 
previous two studies used specific patient groups with n<100, a meta-analysis was conducted 
using 1,378 cases of IDC and 10,383 controls.  This larger survey found HLA-DR4 and HLA-
DR5 had higher associations in patients with IDC [17].  Given the statistical associations 
between IDC, myocarditis, and certain MHC II alleles, these MHC II alleles may have higher 
affinities for epitopes derived the cardiac myosin heavy chain.  Presentation of cardiac epitopes 





 T cells culminating in myocarditis.  Antigen presentation, however, is only one facet of 
CD4
+
 T cell clonal expansion.  For CD4
+
 T cell activation, antigen presenting cells must display 
co-stimulatory molecules, which often require an inflammatory event such as infection or 
cellular damage. 
 
Evidence for myocardial infarction causing myocarditis 
Mounting evidence suggests myocardial infarction (MI) has the potential to lead to 
autoimmune myocarditis.  The uncontrolled release of cardiac epitopes through necrosis and the 
presence of pro-inflammatory cytokines following a myocardial infarction, provide an optimal 
environment for the activation and expansion of cardiac reactive lymphocytes [18].  It has been 
documented in animal models that during the first 3 days following a MI, pro-inflammatory 
macrophages are present in high numbers and therefore are capable of presenting antigens with 
costimulatory molecules [19].  Neutrophils are present during an MI and have been documented 
to cause significant necrosis [18, 19].  High levels of necrosis post MI allow for cardiac antigens 
to be presented in high quantities on APCs.  The potential to activate cardiac specific CD4
+
 T 
cells increases with the duration of an inflammatory environment in cardiac tissue.  Experiments 
in mice and rats provide evidence that cardiac autoimmunity can occur following an MI.  In 
Lewis rats, splenocytes harvested from animals following a myocardial infarction were 
transferred to naïve recipients who subsequently developed myocarditis [20].  Non-obese 
diabetic mice containing human CD4 and human HLA-DQ8 in place of their murine 
counterparts were developed to study type-1 diabetes.  Although these  mice failed to become a 
suitable model for type 1 diabetes, their propensity to spontaneously develop myocarditis made 
this strain optimal for studying autoimmune cardiac inflammation and dilated cardiomyopathy 
[21, 22].  Type 1 diabetic patients commonly possess the HLA-DQ8 allele and are at risk for 
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developing coronary artery disease [23, 24].  The authors hypothesized CD4 HLA-DQ8 NOD 
mice might be at a greater risk of developing myocarditis following MI.  Indeed the authors 
demonstrated after MI, CD4 HLA-DQ8 NOD mice developed myocarditis with lymphocytic 
infiltration and increased IgG antibody production against myocardial antigens [25].  
Furthermore, the authors found auto-antibodies against cardiac myosin in type 1 diabetic patients 



















1.3 CURRENT THERAPIES AND PROGNOSIS FOR 
AUTOIMMUNE MYOCARDITIS 
 
Current therapies for myocarditis mainly consist of immunosuppressive medications to 
inhibit the immune system and pharmacotherapy to minimize blood pressure and workload on 
the heart.  Beta blockers, angiotensin converting enzyme inhibitors, and diuretics are often 
prescribed to patients with myocarditis experiencing symptomatic heart failure [26].  While these 
medications reduce the workload on the heart by reducing systemic blood pressure and 
catecholamine stimulation, they merely treat symptoms caused by the underlying inflammation.  
Steroids and immunoglobulin have had limited success treating myocarditis [27].  
Immunosuppressive treatment is indicated for giant cell myocarditis and eosinophilic 
myocarditis [11, 28].  However, these two types of myocarditis have extremely poor prognoses 
with death often occurring without organ transplant.  The mortality rate for giant cell and 
eosinophilic myocarditis highlight an urgent need for more effective therapies for autoimmune 
myocarditis.  Due to their action of mechanisms, steroidal anti-inflammatory treatment and IVIG 
do not offer a permanent solution as they merely temporarily suppress the immune system and 
do nothing to permanently address cardiac auto-reactive lymphocytes.  Immunosuppressive 
therapies also inhibit the entire immune system and leave patients vulnerable to opportunistic 
pathogens.  Any permanent solution to autoimmune myocarditis will have to specifically address 
lymphocytes that recognize cardiac antigens as they are likely the pivotal immune cells 






Etiology of myocarditis and immunosuppressive therapy 
  Antigen-specific therapy such as GMCSF-antigen fusion proteins would most likely be 
of use in instances of myocarditis where immunosuppressive therapy has been beneficial.  The 
decision to use immunosuppressive therapy in myocarditis is often dictated by the etiology.  
Therefore a review of the etiologies of myocarditis and their benefit from immunosuppressive 
therapy will be reviewed.  Etiologies of myocarditis include systemic autoimmune diseases, viral 
infection of the heart, cardiovascular disease, and etiologies of unknown origin.  When 
myocarditis has a more autoimmune etiology, such as lupus erythematosus, sarcoidosis, and 
hypersensitivity myocarditis, immunosuppression is indicated [29].   
There is extensive literature on the association of viral genomes with myocarditis and 
inflammatory dilated cardiomyopathy [3, 30-32].   In myocarditis of viral etiology, effectiveness 
of immunosuppressive therapy depends on the phase of the disease [33].  If the myocardial viral 
infection is in the initial stage, anti-viral therapy and not immunosuppression is indicated [33].  
Patients with myocarditis due to enteroviral infections respond well to treatment with Interferon-
α or Interferon-β, with clinical improvement lasting 12 months in two thirds of the patients [34].  
However, myocarditic viruses with specific adaptations to inhibit Interferon-β that evade the 
innate immune system have been identified [35].  It is more likely viruses with adaptations to 
avoid the innate immune system will result in more lytic death of cardiomyocytes and have an 
increased chance of activating the adaptive immune system and creating cardiac specific 
lymphocytes.  Perhaps if future research identified more viral subtypes that can evade the innate 
immune system and lead to cardiac auto-reactive lymphocytes, then specific viral etiology could 
be of some clinical diagnostic value when choosing immunosuppression for myocarditis. 
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When the etiology of myocarditis is unknown, as is often the case, characterizing the 
subtype of myocarditis can be of great clinical value when choosing the appropriate treatment.  
Severe acute myocarditis develops in less than 2 weeks and is characterized by progressive 
symptoms of heart failure.  If severe acute myocarditis is caused by necrotizing eosinophilic 
myocarditis or giant cell myocarditis, then immunosuppressive treatment is immediately 
recommended [29, 36, 37].   A small percentage of patients can present with fulminant 
myocarditis where severe symptoms of heart failure are even more sudden and require 
ventricular assist.  However, if patients with fulminant myocarditis survive the initial bout of 
symptoms, there is a very good chance of survival and complete recovery [29].   
 Multiple clinical studies have been conducted to assess the therapeutic potential of 
immunosuppressive therapy in patients with inflammatory dilated cardiomyopathy and 
myocarditis.  A major study published in 1995 investigated the use of azathioprine/cyclosporine 
with prednisone in 111 patients with histological confirmed myocarditis.  The study found no 
significant difference in left ventricular ejection fraction or survival in the group receiving 
immunosuppressive therapy compared to the placebo group [38].  Three subsequent studies 
found significant therapeutic benefit from immunosuppressive therapy, when patients had 





lymphocytes in myocardial biopsies [27, 39, 40].  In summary these clinical studies highlight the 
need for immunosuppressive therapy for myocarditis when there is evidence of an adaptive 





1.4 MYOCARDITIS AND DILATED CARDIOMYOPATHY 
 
Accumulating evidence suggests myocarditis can lead to cardiomyopathy, a serious heart 
condition where the walls of the heart become progressively thinner and less efficient at pumping 
blood.  Dilated cardiomyopathy (DCM) is the leading cause of heart transplant in children [41].  
Because myocarditis is pivotal to the etiology of cardiomyopathy, it is imperative to understand 
the molecular mechanisms underlying myocarditis.  Several lines of evidence indicate that an 
autoimmune etiology may contribute to idiopathic dilated cardiomyopathy.  Because infections 
that cause myocarditis are often subclinical, it is possible a significant percentage of the 
population possess cardiac-specific, auto-reactive lymphocytes that were activated and expanded 
during a previous infection.  These cardiac-specific, auto-reactive T cells could lay dormant for 
years until a new cardiac infection or insult occurs.  Because viral infection is the most common 
known cause of myocarditis in developed countries, one might expect a correlation between 
evidence of past myocardial viral infection(s) and DCM.  A 2005 study designed to address this 
hypothesis found viral genomes in 67% of 245 patients with DCM and 32% of 80 control 
patients [30].  If the adaptive immune system had previously expanded cardiac specific 
lymphocytes, one would also expect to see an increased antibody titer to cardiac proteins.  
Antibodies to the alpha and beta cardiac myosin heavy chains, the beta 1 adrenergic receptor, 
muscarinic receptors, and mitochondrial proteins have been found in patients with myocarditis as 
well as DCM [42].  The adrenergic and muscarinic antibodies have obvious implications for 
cardiac function by binding in an agonist or antagonist manner to their respective receptors.  
Studies have explored this possibility and found that sera from DCM patients could increase the 
heart rate of isolated myocytes in vitro [43]. While antibodies to intracellular cardiac proteins 
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may seem insignificant in a non-inflammatory state, their presence suggests a previous event 
occurred with significant MHC II antigen presentation that could also generate Th1 and/or Th17 
CD4
+
 memory T cells.  Given the proper conditions these memory cells could reactivate and 
exacerbate DCM.  In addition to evidence of viral myocarditis leading to DCM, Rheumatic fever 
and Chagas disease also have a history of DCM.  The abundant number of pathogens with 
documented post infectious myocarditis indicates numerous opportunities for the generation of 



















1.5 ANIMAL MODELS OF AUTOIMMUNE MYOCARDITIS 
 
Animal models of myocarditis provide an invaluable resource to explore the pathogenesis 
of autoimmune myocarditis and allow for testing of novel therapeutics. A search of the current 
literature revealed the most widely used rodent models of experimental autoimmune myocarditis 
(EAM) are Lewis rats, BALB/c mice, and A/J mice.  Lewis rats provide the highest evolutionary 
model of EAM in the rodent family.  The Lewis rat model requires one immunization with 
complete Freund’s adjuvant (CFA) and a myocarditic peptide followed by a booster with 
incomplete Freund’s adjuvant (IFA) and a myocarditic peptide.  In contrast, murine models 
require two CFA/ myosin peptide immunizations.  Although the rat model is probably closer to 
human pathology, murine strains enable mechanistic studies due to the large number of gene 
knockouts in mice that are not available in rats.  Echocardiography provides a noninvasive 
method to characterize the disease progression of EAM.  
A Th1 phenotype is observed in the Lewis rat model of EAM, with high IFN-γ and IL-12 
in the myocardium at onset of disease [8].  This is expected given that CFA is used and heat 
killed mycobacterium normally activates the Th1 pathway.  The disease becomes maximal on 
day 21 with pericardial effusions often present in rats with severe infiltration.  The disease is T 
cell-mediated as studies have shown T cells expanded and activated with myosin 1052-1076 and 
IL-12 are fully capable of inducing severe myocarditis upon transfer to naïve recipients [8].  
Experiments have also shown myosin 1052-1076 can directly bind to toll like receptor 2 and 
provoke pro-inflammatory cytokines from APCs such as monocytes [44].  By stimulating toll 
like receptor 2, myosin 1052-1076 may play a dual role in activating T cells by acting as an 
adjuvant and a stimulatory epitope in the context of MHC II.  T cells harvested from the spleens 
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of Lewis rats immunized with Myosin 1052-1076 can be expanded and maintained in vitro, 
making the model attractive for long term in vitro experiments.  In addition to T cell responses, 
Lewis rats immunized with myosin 1052-1076 have also been shown to develop antibodies 
against the beta adrenergic receptor that are capable of binding with agonist activity [45].  These 
beta adrenergic antibodies with agonist activity can physiologically produce the same effects as 
high levels of epinephrine and contribute to heart failure.    Lewis rats immunized once with 
myosin 1052-1076 in IFA induce IL-10 producing T cells with a more tolerogenic phenotype.  
These myosin 1052-1076 specific T cells can provide protection against EAM when adoptively 
transferred [46].  These data suggest the Lewis rat model is a suitable choice to explore 
therapeutics with a possible T regulatory cell mechanism.  In summary the Lewis rat model is an 
excellent choice to simulate autoimmune myocarditis due to a known myocarditic epitope 
capable of inducing EAM and because rats are easily monitored via echocardiography.  
Autoimmune myocarditis can be elicited in BALB/c and A/J mice.  In both strains of 
mice, myocarditic peptides derived from the alpha cardiac myosin heavy chain have been 
identified that are capable of inducing myocarditis when emulsified in CFA.  The myocarditic 
myosin peptide 614-629 in BALB/c mice appears to be more potent as 100 µg per mouse per 
injection is sufficient [9].  A minimum of 200 µg of myosin 334-352 is required for EAM in A/J 
mice [47].  In most rodent models of EAM inflammation is reported to peak at day 21 and then 
gradually wane over time [48].  At day 21 for BALB/c mice hearts with internal leukocyte 
infiltration appear fairly normally upon removal with no major external lesions or pericardial 
effusion present.  This is in stark contrast to Lewis rats where external lesions covering more 
than 50% of heart surface and pericardial effusions containing as much as 5 ml of fluid are 
commonly observed.   
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One of the major drawbacks of studying EAM in mice is the lack of models in the 
C57BL/6 strain.  A majority of genetic knockouts are maintained on the C57BL/6 background.  
To study a gene of interest in EAM, mice containing the knocked out gene of interest are 
commonly back crossed for multiple generation on to strain that is susceptible.  This process is 
expensive and time consuming.  Previous attempts to induce EAM in C57BL/6 mice using whole 
cardiac myosin heavy chain emulsified in CFA have failed [49].  Using a single antigen in the 
form of a peptide has advantages for inducing EAM.   Peptides are easy to synthesize/ order and 
can be more effective due to the same antigen being present in extremely high quantities.  One 
could argue whole proteins offer more epitopes, but if a significant amount of the protein mass 
does not contribute to antigen recognition, then this mass is effectively wasted.  When purified 
peptides are used to induce experimental autoimmune disease, the recognized epitope is present 
in much higher molar quantities compared to a given epitope in whole protein extracts.  When 
choosing a peptide antigen to induce autoimmune disease in mice, an understanding of the H2 
haplotype is crucial.  Protein derived antigens are presented in the context of MHC II on APC to 
CD4
+
 T cells.  Each allelic version of murine MHC II has an affinity for different peptide 
antigens derived from a protein.  This is why myosin 614-629 induces EAM in BALB/c mice 
with H2-I-A
d
 but this same peptide does not induce EAM in A/J mice which possess H2-I-A
a
.   
 
Hypothesis for EAM in C57BL/6 mice 
Algorithms have been developed to attempt to predict which peptide sequences from a 
protein are likely to bind to a given MHC II allele.  Given that all previous known epitopes 
capable of inducing EAM in mice and rats are derived from the cardiac myosin heavy chain, the 
murine cardiac alpha myosin heavy chain protein was selected to search for peptide antigens 
capable of inducing EAM in mice with the H2-I-A
b 
allele including C57BL/6 mice. The website:  
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http://tools.immuneepitope.org/mhcii/  identified 6 different peptide antigens between residues 
718-737 from murine cardiac alpha myosin heavy chain with predicted high affinity to H2-I-A
b
.  
It was therefore hypothesized that myosin 718-736 would be capable of inducing EAM in mice 























1.6 CYTOKINE ANTIGEN FUSION PROTEINS AND 
AUTOIMMUNE DISEASE 
 
Cytokine-peptide fusion proteins have demonstrated efficacy in the treatment of 
experimental autoimmune encephalomyelitis (EAE) in rats and mice [50-59].  Specifically the 
cytokine neuroantigen fusion proteins have been able to inhibit disease when EAE is induced by 
the same antigen used in the fusion protein.   Studies have explored linking an encephalitic 
antigen to various cytokines.  Of the cytokines tested in neuroantigen fusion proteins, some were 
more potent than others at inhibiting EAE.  From most inhibitory to least inhibitory GM-CSF, 
IL-16, IL-2, M-CSF, IL-4, IL-13, and IL1RA were found to attenuate EAE when covalently 
linked to a neuroantigen [53].  The most potent cytokine found to inhibit EAE was GM-CSF.  
GM-CSF neuroantigen fusion proteins have successfully inhibited EAE when delivered in 
pretreatment and treatment regimens for Lewis rats, SJL mice and C57BL/6 mice [50, 53-55].  In 
vitro experiments confirmed GMCSF-antigen fusion proteins were able to activate T cell lines 
specific for the covalently attached antigen [55].  The fusion proteins were 10 to 1,000 fold more 
potent at stimulating antigen specific T cells compared to free antigen, suggesting the GM-CSF 
fusion proteins were targeting antigen presenting cells [55].  Indeed competitive inhibition 
experiments in which free unconjugated GM-CSF was added in increasing concentrations to 
GMCSF-NAg confirmed the cytokine portion of the fusion protein was targeting myeloid APCs 
and enhancing uptake of the fusion protein via GM-CSF binding to its cognate receptor [55].  To 
confirm that the covalent bond between GM-CSF and the neuroantigen was necessary for 
inhibition of EAE, experiments were conducted in which an equal molar mix of MOG35-55 + 
GM-CSF or GP69-88 + GM-CSF was compared to the same number of moles of fusion protein 
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[54].  The investigators found the covalent bond between GM-CSF and the neuroantigen was 
absolutely necessary for the inhibition of EAE in Lewis rats and C57BL/6 mice in pretreatment 
and treatment experiments [54, 55].  In addition to inhibiting actively-induced EAE, GMCSF-
MOG was also tested against EAE induced by adoptive transfer of activated MOG 35-55 T cells 
[54].  Mice treated with GMCSF-MOG on days 9, 11, and 14 post adoptive transfer had a 
significantly milder course of EAE compared to control animals.  In summary, GMCSF-NAg 
fusion proteins are potent tolerogenic vaccines against EAE that operate through antigenic 
targeting and most likely alter the phenotype of APCs due to signaling from the cytokine portion 
of the fusion protein.  Given their potent ability to inhibit EAE, GMCSF-antigen fusion proteins 
may well be effective against other models of autoimmune disease including experimental 
autoimmune myocarditis.  
 
Hypothesis for GMCSF-Myosin fusion proteins treating EAM 
Given the previous success of antigen specific inhibition of EAE using GMCSF-NAg 
fusion proteins, it is hypothesized that GMCSF-Myosin fusion proteins will be able to inhibit 
myocarditis in experimental autoimmune myocarditis in Lewis rats and BALB/c mice.  These 
models were chosen because myosin derived epitopes capable of inducing myocarditis have been 
identified.  It is hypothesized that GMCSF-Myosin fusion proteins will at minimum provide 
protection against myocardial inflammation when EAM is induced by the same antigen present 





   
 
Chapter 2 
Materials and Methods 
 
2.1 CREATING VECTORS CODING FOR GMCSF-MYO614 
AND GMCSF-MYO334  
 
GMCSF-Myo614 and GMCSF-Myo334 were created by expanding primers to yield a 
double stranded DNA segment with the following order: 5’-GM-CSF overlap-Myosin peptide-
histidine tag-vector overlap-3’. These expanded primer segments were then extended against a 
pIRES2 vector already containing GMCSF-PLP178.  The product containing pIRES2 with the 
new fusion proteins was used to transfect HEK 293F cells which were sorted for isolation of 
cells producing high quantities of the transfected proteins. 
 
GMCSF-Myo614 
For GMCSF-Myo614, primer 4 and primer 5 were expanded to create a 90 bp segment, 
GMCSF-Myo614 fragment 1.  This 90 bp sequence was then expanded with primers 3 and 7 to 
produce a 144 bp segment, GMCSF-Myo614 fragment 2.  The 144 bp segment was expanded 
with primers 1 and 11 to yield a 178 bp fragment, GMCSF-Myo614 fragment 3.  The 178 bp has 
the following order: 5’-GMCSF overlap-Myosin 614-643 peptide-histidine tag-vector overlap-3’.  
This 178 bp fragment was extended against GMCSF-PLP178 in a pIRES2 vector to produce full 
length pIRES2 vector containing GMCSF-Myo614 with a size of 5805 bp.  The product from the 
extension reaction was digested with Afel I and Dpn I to eliminate residual GMCSF-PLP178 





To create GMCSF-Myo334 primers were expanded via two PCR reactions.  The first 
reaction with primers 2 and 6 created a 111 bp segment, GMCSF-Myo334 fragment 1.  The 111 
bp fragment was further expanded using primers 1 and 10 to create a 145 bp fragment, GMCSF-
Myo334 fragment 2, with 5’-GM-CSF overlap-Myo 334-352 peptide-histidine tag-vector 
specific overlap-3’.  The 145 bp fragment was used with GMCSF-PLP178 in pIRES2 to create a 
full length GMCSF-Myo334 inside the pIRES2 vector with a size of 5297 bp.  This product was 
then digested with Afel I and Dpn I to remove residual GMCSF-PLP178 template and 
methylated DNA respectively. 
The pIRES2 vector containing GMCSF-Myo614 or GMCSF-Myo334 was added to top10 
E. coli for transformation via electroporation.  The electroporated E. coli were cultured on agar 
plates containing (50 µg/ml) kanamycin.  After 15 hours of growth single colonies were selected 
and grown for one hour in 100 µl of LB containing 50 µg/ml kanamycin in preparation for whole 
cell polymerase chain reaction (PCR).  Whole cell PCR was setup using 1 µl from each colony 
with primers 12 and 13 to produce a fragment containing 5’-GMCSF overlap-peptide sequence-
histidine tag-vector overlap-3’.  Because the PLP 178-192 peptide contains a recognition site for 
the Afel I restriction endonuclease, PCR product from colonies transfected with GMCSF-
PLP178 should digest into two fragments with the larger fragment equaling 535 bp.  PCR 
amplification using the vector specific primers 12 and 13 should yield a 676 bp for GMCSF-
Myo614 and a 643 bp fragment for GMCSF-Myo334.  Therefore all whole cell PCR products 
were digested with Afel I and run on an agarose gel to identify colonies containing GMCSF-





Table 2.1 Primers for GMCSF-Myo614 and GMCSF-Myo334 
 
 























Vector sequencing and eukaryotic transfection 
Glycerol stocks containing GMCSF-Myo614 or GMCSF-Myo334 were streaked for 
isolation and individual colonies were expanded in LB containing kanamycin (50 µg/ml) for 15 
hours at 37
0
C.  Approximately 5 ml of expanded clones for GMCSF-Myo614 or GMCSF-
Myo334 was used to isolate DNA plasmid using the Qiagen Plasmid Mini Prep kit.  Purified 
plasmid with primers 12 and 13 were sent to GeneWiz.com for sequencing.  Multiple clones 
from each fusion protein were identified with perfect sequences, however only one clone for 
each fusion protein was selected for eukaryotic transfection.  Clone 2 for GMCSF-Myo614 and 
clone 1 for GMCSF-Myo334 were chosen for expansion and transfection.  Glycerol stocks for 
each clone were streaked for isolation on agar plates containing kanamycin (50 µg/ml).  An 
isolated colony for each fusion protein was expanded in 50 ml of LB containing kanamycin (50 
µg/ml) for 15 hours.  The bacteria were then harvested and used in Midi preps (Qiagen) to isolate 
vector plasmid.  37.5 µg of plasmid for each fusion protein was used with lipofectamine (Life 
Technologies) to transfect HEK 293F cells.  Transfected HEK 293F cells were cultured with 
Geneticin to positively select pIRES2 transfected cells.  Transfected cells were then sorted for 
green fluorescent protein (GFP) production using a 488 nm laser on a Becton Dickinson 
FACSVantage SE high speed cell sorter.  Approximately 100,000 high GFP cells for each fusion 
protein were sorted and expanded in culture using cRPMI (1640 media with 10% heat 
inactivated fetal bovine serum) with Geneticin.  Freezer stocks were made by adding 10 million 
cells to cRPMI in 10% DMSO.  The cells were frozen at -80
0
C for 24 hours and then transferred 





2.2 GMCSF-MYO1052 EXPRESSION 
 
Baculovirus stock coding for GMCSF-Myo1052 or GM-CSF was removed from liquid 
nitrogen and scraped with an 18 gauge needle to remove a very small amount of virus.  This ice 
scraping was used to expand the virus by infecting approximately 20 million cells plated on 150 
mm diameter polystyrene dish with 20 ml of SF9 expression media.  The cells were cultured at 
standard atmospheric conditions with no light for approximately 8 days and upon visual 
confirmation of viral infection the supernatant was harvested and used for protein expression.  1 
ml of the expanded virus stock and 19 ml of serum free media was added to a 150 mm diameter 
plate with 10 million naïve insect cells and cultured at standard atmospheric conditions with no 
light for approximately 4 days.  The supernatant was then collected and spun at 4000 G for 12 
minutes to remove cellular debris and stored at -20
0













2.3 GMCSF-MYO614 AND GMCSF-MYO334 EXPRESSION 
 
Before HEK 293 F cells were used for fusion protein expression, production of GFP was 
assessed as an indirect measure of GMCSF-Myo614 expression.  Naïve HEK cells were 
compared against GMCSF-Myosin transfected cells on a flow cytometer using a 488 nm laser 
with detection set at 505 nm.  If fluorescence of the transfected cells at 505 nm was at least two 
orders of magnitude higher than naïve HEK cells, the transfected cells were used for protein 
production.  HEK 293 F cells containing pIRES2 coding for GMCSF-Myo614 or GMCSF-
Myo334 were seeded at 20 million cells in 30 ml of Serum Free 293 Expression Medium (Life 
Technologies) containing 0.4 mg/ml of Geneticin (G418, Life Technologies) in a 125 ml plain 
bottom vented shaker flask (Fisher Scientific).  Culture conditions consisted of 5% CO
2
, 80% 
humidity, and constant circular shaking in the dark.  The cells were allowed to double twice over 
48 hours at which time all supernatant was collected, spun at 4000 G for 12 minutes and stored at 
-20
0
C.  The cells were diluted back to 20 million per flask using the same culture conditions.  
This process was repeated until 1 to 2 liters of supernatant was accumulated, at which point the 










2.4 PROTEIN CONCENTRATION AND PURIFICATION 
 
For GM-CSF, GMCSF-Myo1052, GMCSF-Myo614, and GMCSF-Myo334 frozen 
supernatant was thawed and centrifuged at 4000 G for 12 minutes followed by sterile filtration to 
remove debris.  The filtered supernatant was added to a pressurized Amicon Stir cell system 
(Millipore, Billerica, MA) with a YM10 ultrafiltration Membrane (Millipore) to concentrate all 
protein from approximately one liter to about 25 ml.  For protein expressed in the insect cell 
system an extra diafiltration procedure was conducted where the 25 ml was expanded to 300 ml 
with wash buffer and concentrated again to 25 ml.  This diafiltration step was not necessary for 
protein produced in the HEK 293 F system.  
The 25 ml of concentrated protein was further concentrated and purified using two passes 
over a Ni-NTA column.  The nickel column was first equilibrated with 10.0 ml of wash buffer 
(50 mM NaH2PO4 (monobasic and anhydrous), 500 mM NaCl, pH 8.0) containing 10 mM 
imidazole.  After equilibrating the column the 25 ml containing the protein was added in 1 ml 
increments.  The column was then washed with 10 ml of wash buffer containing 10 mM 
imidazole and then eluted with 6 ml of wash buffer containing 250 mM imidazole.  The eluted 
protein was washed with approximately 13 ml of wash buffer 3 times using an Amicon ultra 15 
tube (Millipore, Billerica, MA).  The nickel column was again equilibrated with wash buffer 
containing 10 mM imidazole and the retentate from the Amicon ultra 15 was added.  The column 
was washed with 10 ml of wash buffer containing 10 mM imidazole.  Next 2 ml fractions 
containing increasing concentrations of imidazole (20 mM, 40 mM, 60 mM and 100 mM) were 
added.  2 ml from each concentration was collected in a separate tube.  Finally any remaining 
protein was eluted using 3 x 2ml fractions of wash buffer containing 250 mM imidazole.  
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SDS PAGE was performed to determine which elution fractions contained the fusion 
protein.   The fractions were diluted 1:2 using loading buffer (100 mM Tris-HCl, 4% SDS, 0.2% 
bromophenol blue, 20% glycerol, 200 mM beta-mercaptothethanol) and heated for 10 minutes at 
90
0
C prior to loading.  The gels contained a 5% stacking layer and a 12% resolving layer 
containing 30% bisacrylamide, Tris-HCl (pH 6.8 or 8.8), 10% SDS, 10% ammonium persulfate, 
TEMED, and MilliQ water.  The samples were run at 60 milliamps through the stacking layer 
and 90 milliamps through the resolving layer until the leading edge of the loading dye reached 
the end of the gel.  The gels were then fixed using 50% methanol, and 8% acetic acid for 15 
minutes before being stained overnight with a Coomassie-based dye.  The next morning the gel 
was washed repeatedly in MilliQ water and pictures were acquired using a BioRad Gel doc 
system.   
Fractions identified from SDS PAGE containing the protein were combined in an 
Amicon ultra 15 tube and washed three times with wash buffer containing no imidazole.  The 
final 400 µl fraction containing the protein was expanded to 1 ml with sterile PBS and analyzed 
at 280 nm on a nanodrop 1000 to determine the final protein concentration.  The protein was then 
aliquoted and stored at -80
0










2.5 FUSION PROTEIN VALIDATION 
 
Cytokine domain validation 
The GM-CSF cytokine domain of GMCSF-Myo1052, GMCSF-Myo614 and GMCSF-
Myo334 was validated using bone marrow proliferation assays with [3H]thymidine.    A 96 well 
flat bottom plate was used to serially dilute GMCSF-Myo1052 or GM-CSF in triplicate using 
cRPMI supplemented with FBS from one micromolar to one picomolar in full log steps.   All 
wells had 100 µl of volume after the serial dilution.  For GMCSF-Myo1052, bone marrow was 
harvested from the femurs of Lewis rats.  For GMCSF-Myo614 and GMCSF-Myo334, bone 
marrow was harvested from the femurs of BALB/c mice.  The bone marrow cells were washed 
twice in HBSS and counted using a hemocytometer.  55,000 bone marrow cells were added to 
each well in 100 µl of cRPMI, leaving 200 µl per well final volume.  The cells were incubated at 
37
0
C with 5% CO
2
 and 80% relative humidity.  After 48 hours of total incubation, 20 µl of 
[3H]thymidine (1 µCi / well, Perkin Elmer, Waltham, MA.) was added to each well.  After 72 
hours of total culture the cells were harvested onto a filter for 96 well plates using a Tomtec 
Mach III harvester.  The filters were screened for [3H]thymidine incorporation using a Wallac 
1450 Microbeta Plus liquid scintillation counter. 
 
Antigen domain validation 
Antigen presentation of Myosin 1052-1076 from GMCSF-Myo1052 was assessed using 
irradiated splenocytes and a Lewis rat derived, stable T cell line specific for myosin 1052-1076.  
GMCSF-Myo1052 or myosin 1052-1076 was titrated in triplicate in a 96 well plate using cRPMI 
supplemented with 10% FBS from one micromolar to 10 femtomolar in full log dilutions.  
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Myo1052 T cells were counted, washed twice with HBSS to remove any residual IL-2, and 
plated at 25,000 cells per well in cRPMI.  A spleen was harvested from a Lewis rat, irradiated, 
and processed into a single cell suspension.  The splenocytes were washed twice with HBSS 
counted and plated at 250,000 cells per well in cRPMI.  The final volume for each well was 200 




, 80% relative humidity in complete 
darkness.  After 24 hours of incubation, 100 µl of supernatant was removed for IL-2 analysis and 
100 µl of fresh cRPMI was added back to each well.  After 48 hours of total incubation, 20 µl of 
[3H]thymidine (1 µCi / well, Perkin Elmer, Waltham, MA.) was added to each well.  After 72 
hours of total culture the cells were harvested onto a filter for 96 well plates using a Tomtec 
Mach III harvester.  The filters were screened for [3H]thymidine incorporation using a Wallac 
1450 Microbeta Plus liquid scintillation counter. 
Twenty four hours after Myosin 1052 T cells were activated, supernatants were collected 
and assayed for IL-2 production by culturing CTLL cells in the presence of MTS/PMS 
(Promega, Madison, WI).  CTLL cells require IL-2 for growth, and are therefore suitable for 
assaying IL-2.  CTLL cells were washed twice with HBSS to remove any residual IL-2.  The 
cells were suspended in cRPMI at 100,000 cells/ml, and 100 µl was added to each well giving 
10,000 CTLL cells per well with total volume of 200 µl per well.  After 48 hours of culture, the 
CTLL cells were pulsed with 10 µl of 1% PMS in MTS.  After 72 hours of culture, optical 
density was measured at 490 nm.   
To confirm GMCSF-Myo1052 was presented via MHC II to CD4
+
 T cells, two antibody 
inhibition experiments were conducted.  For both experiments, GMCSF-Myo1052 was added to 
six columns of a 96 well plate, while myosin 1052-1076 was added to the remaining six 
columns.  For both experiments, GMCSF-Myo1052 and myosin 1052-1076 were titrated in full 
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log dilutions from one micromolar to 1 picomolar.  For one experiment 2.0% of W3/25 (a 
monoclonal antibody specific for CD4 in rats) was added to each well.  For the other experiment 
2.0% of OX6 (monoclonal antibody against MHC II) was added to three columns with GMCSF-
Myo1052 and three columns with myosin 1052-1076.  An isotype control antibody against IL-4 
was added to the remaining wells for the second experiment.  For both experiments, 25,000 
myosin 1052-1076 specific T cells were rested and washed prior to being added to each well.  
For both experiments, 250,000 irradiated splenocytes from a naïve Lewis rat were added to each 
well.  All cells and proteins were added using cRPMI and each well contained a final volume of 
200 µl of cRPMI.  Cells were pulsed with [3H]thymidine at 48 hours and harvested at 72 hours 















2.6 EAM INDUCTION, MONITORING, AND SCORING 
 
Lewis rat Active EAM 
Experimental autoimmune myocarditis was induced in Lewis rats using two injections of 
myosin 1052-1076 (KRKLEGDLKLTQESIMDLENDKQQL).  On day 0, each rat received two 
100 µl subcutaneous injections containing 500 µg of myosin 1052-1076 emulsified in 100 µl of 
PBS, 50 µl of Complete Freund’s Adjuvant (200 µg Mycobacterium tuberculosis in Incomplete 
Freund’s Adjuvant (Difco, Detroit, MI)), and 50 µl of IFA delivered  at the base of the tail .  On 
days 0 and 3, each rat received an intraperitoneal injection containing 0.2 µg of Pertussis toxin 
(Millipore) in 0.5 ml of PBS.  On day 7, each rat received two 100 µl subcutaneous booster 
injections containing 500 µg of myosin 1052-1076 emulsified in 100 µl of PBS and 100 µl of 
IFA delivered at the base of the tail.  For active EAM induction animals were euthanized on day 
21 using 90:10 mg/ml Ketamine/Xylazine (0.05 ml/10 g body weight).  The only exception of 
euthanasia on day 21 for active EAM was the longitudinal experiment, where rats were 
euthanized with Ketamine/Xylazine on days 14, 21, 28, and 50.   The hearts were removed, the 
atria were cut off and the ventricles were flushed with cold PBS and placed in approximately 10 
ml of zinc fix (100 mM Tris buffer, 3.16 mM Calcium Acetate, 22.78 mM Zinc Acetate, 36.68 
mM Zinc Chloride) for one week at 4
0
C.  The hearts were cut three times from apex to base 
generating four separate pieces which were placed in a tissue cassette and dehydrated using 
ethanol and xylene in preparation for paraffin embedding.  The paraffin blocks were sliced to 
create 0.5 µm sections which were stained with hematoxylin and eosin.  The hearts were then 
scored to assess infiltration using the following scale: 0 = normal myocardium, 1 = mild 
myocarditis (<5% cross section infiltrated), 2 = moderate myocarditis (5-10% cross section 
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infiltrated), 3 = marked myocarditis (10-25% cross section infiltrated), 4 = severe myocarditis 
(>25% cross section infiltrated). 
 
Lewis rat Passive EAM 
Passive EAM was induced in Lewis rats using adoptive transfer.  Two donor rats were 
injected with 500 µg of myosin 1052-1076 emulsified in 0.05 ml of PBS and 0.05 ml of CFA.  
0.2 µg of pertussis toxin in 0.5 ml of saline was administered via intraperitoneal injection to 
donor rats on days 1 and 3.  On day 14, the donor rats were euthanized and their spleens were 
collected and homogenized into a single cell suspension.  The cells were cultured at 2.7 million 
cells per ml in cRPMI with 0.4% IL-12 (from SF-9 expression) and 1 µM myosin 1052-1076.  
After 3 days of culture, six recipient rats each received 22 million activated donor cells via 
intraperitoneal injection.  Four of the recipient rats were euthanized on day 14 post injection 
while the remaining 2 rats were euthanized on day 19 post injection.  The hearts were fixed in 
zinc fix, paraffin embedding, stained with H&E and scored as previously described for active 
EAM in Lewis rats. 
 
BALB/c and C57BL/6 Mice  
Experimental Autoimmune myocarditis was induced in BALB/c mice and C57BL/6 mice 
using myosin 614-629 (SLKLMATLFSTYASAD) and myosin 718-736 
(GDFRQRYRILNPAAIPEGQ) respectively.  For BALB/c mice, 100 µg of myosin 614-629 was 
emulsified in 0.05 ml of PBS and 0.05 ml of CFA and delivered via two 0.05 ml subcutaneous 
injections at the base of the tail on day 0 and day 7.  Interferon gamma receptor 1 deficient mice 
(Ifngr1
 -/-
)(B6.129S7-Ifngr1tm1Agt/J; stock No. 003288), B cell–deficient mice (Ighm -/-





) (B6.129P2-Nos2tm1Lau/J, stock 002609), and wildtype C57BL/6 mice received 
200 µg of myosin 718-736 emulsified in 0.05 ml of PBS and 0.05 ml of CFA via two 0.05 ml 
subcutaneous injections at the base of the tail on day 0 and day 7.  For both strains of mice 0.2 
µg of pertussis toxin (Millipore) in 0.5 ml of PBS was administered via intraperitoneal injection 
on day 0.  All mice were euthanized on day 21 using 18:2 mg/ml Ketamine/Xylazine (0.05 ml/10 
g body weight).  The hearts were placed in zinc fix (100mM Tris buffer pH=7.4, calcium acetate 
3.16mM, zinc acetate 27.25mM, zinc chloride 36.68mM), dehydrated, paraffin embedded, 
stained with H&E, and scored as previously described for Lewis rats.  
 
Activation of Myosin 718 splenocytes 
Two female Ifngr1
 -/-
 mice on the C57BL/6 background were injected with 200 µg of 
myosin 718-736 emulsified in 0.05 ml of saline and 0.05 ml of CFA on day 0 and day 7.  One of 
the two female mice also received 0.2 µg of pertussis toxin in 0.5 ml of saline via intraperitoneal 
injection on day 0.  On day 14 both mice were euthanized and their spleens were harvested and 
homogenized into a single cell suspension.  The splenocytes were washed twice with HBSS and 
suspended in cRPMI at 2.5 million cells per ml.  250,000 splenocytes in 100 µl of cRPMI were 
added to each well of a 96 well plate.  The plate already contained 100 µl of myosin 718-736, 
myosin 721-735, myosin 614-629, or myosin 1052-1076 in triplicate full log dilutions from 10 
micromolar to 10 picomolar.  After 48 hours of total incubation, 20 µl of [3H]thymidine (1 µCi / 
well, Perkin Elmer, Waltham, MA.) was added to each well.  After 72 hours of total culture the 
cells were harvested onto a filter for 96 well plates using a Tomtec Mach III harvester.  The 






Echocardiography was performed in both rats and mice using a Vevo 2100 (Visual 
Sonics, Toronto, Canada) imager to noninvasively assess myocarditis.  Isoflurane was used for 
anesthesia.  Rats were maintained at approximately 2% isoflurane with 100% O
2
 while mice 
were maintained at approximately 1% isoflurane with 100% O
2
.  In all rodents, Nair was used in 
a depilatory manner to remove hair.  Images were captured in rats using a MS250 transducer at 
13-24 MHz.  In mice a MS400 transducer at 18-38 MHz was used.  Images were acquired in M 
mode using parasternal long axis and short axis views.  Images were subsequently marked to 
measure left ventricular inner diameter and left ventricular posterior wall thickness in both 
systole and diastole.  Heart rate was also measured to ensure the animals were not overly 
anesthetized.  The images were also examined for the presence of pericardial effusion by 













2.7 FUSION PROTEIN PRETREATMENT AND TREATMENT 
REGIMENS 
 
Pretreatment experiments were conducted in Lewis rats and BALB/c mice to determine if 
GMCSF-Myo1052 and GMCSF-Myo614 could inhibit EAM in their respective models.   A PBS 
group was included to control for the vehicle.   A myosin 1052-1076 group and a myosin 614-
629 group were included to control for immune tolerance in Lewis rats and BALB/c mice 
respectively.  In Lewis rats all fusion protein batches used in animal experiments were 
previously tested for cytokine bioactivity and antigen presentation.  In BALB/c mice all fusion 
proteins used for animal experiments were previously tested for cytokine bioactivity.  On days -
21, -14 and -7 Lewis rats or BALB/c mice were subcutaneously injected on both sides at the base 
of the tail with vehicle (PBS for Lewis rats and saline for BALB/c mice), 2.5 nanomoles of 
peptide (myosin 1052-1076 for Lewis rats or myosin 614-629 for BALB/c mice), or 2.5 
nanomoles of fusion protein (GMCSF-Myo1052 for Lewis rats or GMCSF-Myo614 for BALB/c 
mice).  EAM induction began on day 0 as previously described.  Hearts were harvested for 
histology on day 21 and scored as previously described.  
Treatment experiments were conducted in BALB/c mice to evaluate the ability of 
GMCSF-Myo614 to inhibit or attenuate actively developing disease in EAM.  A saline group 
was present to control for vehicle.  A myosin 614-629 group was included to control for immune 
tolerance to the myosin antigen.  GMCSF-Myo334 was included to control for any effects due to 
the presence of GM-CSF.  The 334 epitope of GMCSF-Myo334 should not be presented on 
MHC II glycoproteins in BALB/c mice due to the absence of the H2-I-A
a
 allele and therefore 
GMCSF-Myo344 can effectively serve as cytokine control in BALB/c mice.  EAM induction 
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started on day 0 as previously described.  Mice were injected on days 10, 12, 14, and 16 with 
saline, myosin 614-629, GMCSF-Myo334, or GMCSF-Myo614.  For peptide or fusion protein 
injections each mouse received 2 nanomoles of their respective molecule each injection day.  
Upon euthanasia on day 21, hearts were collected for histology while whole blood was collected 




















3.1 EXPRESSION AND VALIDATION OF GMCSF-MYO1052 
FOR THE LEWIS RAT MODEL OF EAM 
 
GMCSF-Myo1052 was expressed using the SF-9 insect cell system, concentrated by use 
of Millipore filters, and finally purified with a nickel column.  Baculovirus encoding GMCSF-
Myo1052 was expanded by two passages and then used to infect naïve insect cells.  Supernatant 
was harvested after approximately 7 days of culture and concentrated using filters that allowed 
proteins 10 kilodaltons and smaller to pass through.  Because GMCSF-Myo1052 has a weight of 
18,484 daltons, the protein was retained above the membrane.  GMCSF-Myo1052 was purified 
by two passes over a nickel column.  Because GMCSF-Myo1052 contains an 8 residue histidine 
tag on the C terminus, the protein readily binds nickel.  The first pass over the nickel consisted of 
a 10 mM wash with imidazole followed by elution with 250 mM imidazole.  This first pass is 
designed to remove any proteins with low affinity to the nickel column.  The second pass 
consists of increasing concentrations of imidazole designed to elute proteins produced by the 
insect cells with weak to moderate affinity to the nickel column.  In Figure 3.1 nonspecific 
proteins are shown eluting from the nickel column using 40 mM to 100 mM concentrations of 
imidazole.  The 250 mM elution resulted in relatively pure GMSF-Myo1052 which was washed 
to remove imidazole prior to in vivo use.  Assays were conducted to validate the bioactivity of 
the cytokine domain prior to use in Lewis rats.  To validate the cytokine domain bone marrow 
cells harvested from the femurs of Lewis rats were cultured with increasing concentrations of 
GMCSF-Myo1052 or GM-CSF.  Figure 3.2 shows an equal increase in cellular proliferation 
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between GMSF-Myo1052 and GM-CSF.  These data indicate covalent attachment of myosin 
1052-1076 to the C terminus of GM-CSF does not impair cytokine bioactivity.   
To assess bioactivity of the antigen domain myosin, 1052-1076 specific T cells were 
cultured with irradiated splenocytes and increasing concentrations of GMCSF-Myo1052 or 
myosin 1052-1076.  Figure 3.3 (A) shows enhanced T cell proliferation as measured by 
[
3
H]thymidine with GMCSF-Myo1052 versus myosin 1052-1076 peptide.  GMCSF-Myo1052 
displays high proliferation at lower concentrations compared to myosin 1052-1076 and indicates 
receptor mediated uptake with subsequent antigen presentation is likely occurring.  In addition to 
[
3
H]thymidine incorporation, 100 µl of supernatant was removed from each well after 24 hours 
of growth to measure IL-2 production.  Expanding/activated CD4
+
 T cells produce high levels of 
IL-2 for autocrine use as a growth factor.  Therefore IL-2 levels can be used as a surrogate 
marker of CD4
+
 T cell activation.  The supernatant was transferred to a blank 96 well plate 
which was used to culture CTLL cells.  CTLL proliferation, in the presence of the supernatant, 
was assessed using MTS/PMS and measured at 492 nm.  Figure 3.3 (B) represents CTLL growth 
which can be used as a surrogate for IL-2 production.  Figure 3.4 shows enhanced IL-2 
production from GMCSF-Myo1052 compared to myosin 1052-1076.  Data from a single 
experiment in figure 3.3 confirm enhanced bioactivity of the antigen domain of GMSCF-
Myo1052 in the presence of splenocytes as APCs.   
To confirm the antigen domain of GMCSF-Myo1052 was being presented via MHC II to 
CD4
+
 T cells, antibody inhibition assays were conducted.  Myosin specific 1052-1076 T cells 
were cultured with irradiated splenocytes and increasing concentrations of GMCSF-Myo1052 or 
myosin 1052-1076.  In Figure 3.4 (A) cultures contained either OX6 (anti MHC II) or an isotype 
control/OX81 (anti IL-4).  OX6 completely inhibited growth in the presence of GMSF-Myo1052 
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or myosin 1052-1076.  In Figure 3.4 (B) W3/25 (anti CD4) reduced T cell growth in the presence 
of GMCSF-Myo1052 or myosin 1052-1076.  This reduced response from W3/25 is expected as 




















Figure 3.1 Expression of GMCSF-Myo1052 
SDS PAGE was performed to identify which fractions eluted from the nickel column 
contained GMCSF-Myo1052.  Significant quantities of nonspecific proteins are seen eluting at 
lower imidazole concentrations (40 mM to 100 mM) while relatively pure GMCSF-Myo1052 is 






























Figure 3.2 Validation of the cytokine domain of GMCSF-Myo1052 
To validate the cytokine domain of GMCSF-Myo1052, two preparations of GMCSF-
Myo1052 were tested in a bone marrow proliferation bioassay. The GMCSF-Myo1052 and GM-
CSF preparations had essentially equipotent cytokine activity. The EC50 values for GMCSF-
Myo1052 preparation 1, GMCSF-Myo1052 preparation 2, and GM-CSF were respectively 893 


























Figure 3.3 Validation of the antigen domain of GMCSF-Myo1052 
The antigenicity of the peptide domain of GMCSF-Myo1052 was assessed by measuring 
the activation of Myosin 1052 specific T cells in the presence of irradiated splenocytes with 
increasing concentrations GMCSF-Myo1052 or myosin 1052-1076.  After 48 hours all cells 
were pulsed with [3H]thymidine and at 72 hours all cells were harvested for [3H]thymidine 
counts.  [3H]thymidine counts in (A) show the antigenic response to GMCSF-Myo1052 was 
approximately 1000-fold more potent than the response to myosin 1052-1076.   
Activation of the myosin specific T cells was also assessed by measuring IL-2 production 
from 100 µl of supernatant collected 24 hours after activation.  IL-2 was measured with CTLL 
cells and MTS/PMS. Figure 3.3 (B) shows a consistent pattern of activation where an increase in 
IL-2 from T cells cultured with GMCSF-Myo1052 started at 10 nM while an increase in IL-2 









Figure 3.4 The Antigenic domain of GMCSF-Myo1052 is presented via MHC II to CD4+T 
cells 
To verify that GMCSF-Myo1052 stimulated the expansion of CD4
+
 T cells via cells 
displaying myosin 1052-1076 on MHC II, assays were performed in the presence or absence of 
neutralizing anti-MHC II or anti-CD4 monoclonal antibodies (mAb).  Proliferation of myosin 
1052-1076 specific T cells in the presence of irradiated splenocytes and GMCSF-Myo1052 or 
myosin 1052-1076 was completely blocked by anti-I-A MHCII-RT1B (OX6) and was inhibited 



















3.2 EFFICACY OF GMCSF-MYO1052 IN THE LEWIS RAT 
MODEL OF EAM 
 
After validating both domains of GMCSF-Myo1052 and demonstrating evidence 
suggesting that the antigen domain of GMCSF-Myo1052 is presented by MHC II to CD4
+
 T 
cells, experiments were designed to test the efficacy of GMCSF-Myo1052 in the Lewis rat 
model of EAM.  Because GMCSF-Myo1052 was hypothesized to attenuate EAM in Lewis rats 
by modulating the T cell repertoire, it was deemed prudent to insure and validate that myosin 
1052-1076 induced EAM was a T cell mediated disease.  Limited data has been published 
demonstrating EAM induced with myosin 1052-1076 in Lewis rats is T cell mediated.  Therefore 
an adoptive transfer experiment was conducted to validate previous findings that myosin 1052-
1076 induced EAM in Lewis rats is T cell mediated.  Adoptive transfer was performed by 
injecting rats once with myosin 1052-1076 in CFA.  Fourteen days after this injection, 
splenocytes were harvested and expanded and activated in vitro using myosin 1052-1076 and IL-
12.  These activated T cells were then injected in naïve recipients and euthanized at days 14 and 
19.  Figure 3.5 demonstrates T cells activated with myosin 1052-1076 and IL-12 are sufficient to 
induce severe EAM.  Figure 3.6 shows myosin 1052-1076 induced EAM in the Lewis rat is a T 
cell mediated disease. 
True autoimmune myocarditis is a self-perpetuating disease that can cycle in severity 
over time and is not limited to one acute occurrence.  To better define the potential for chronic 
disease in the Lewis rat model of EAM, a longitudinal study was conducted.  Instead of 
euthanizing all subjects at day 21, rats were divided into 4 four groups and euthanized on days 
14, 21, 28 or 50.  Figure 3.6 shows severe myocarditis at day 50.  These data indicate actively 
induced EAM with myosin 1052-1076 has the potential to manifest as a chronic disease that can 
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persist well past the published 3 week typical maximum reported in the literature.   The chronic 
inflammation in Figure 3.6 parallels data reported on autoimmune myocarditis in clinical 
literature. 
To test the hypothesis that GMCSF-Myo1052 could inhibit myosin 1052-1076 induced 
EAM in Lewis rats, a pretreatment experiment was performed.  GMCSF-Myo1052 was given 
once a week for three weeks prior to active EAM induction.  Figure 3.7 shows animals receiving 
GMCSF-Myo1052 generally had minimal inflammation or no inflammation while animals 
receiving the myosin peptide control or PBS vehicle control had significantly higher levels of 
myocardial infiltration.  These data indicate pretreatment with GMCSF-Myo1052 provides 
significant protection against myocarditis in Lewis rats when EAM is induced with the same 
antigen present in the fusion protein.  Figure 3.8 shows histological cross sections of a (A) 
normal rat heart and (B) rat heart experiencing level 4 infiltration (>25% cross section 
infiltration).  In (C) and (D), a normal heart and a heart with level 4 infiltration, respectively, are 
shown in parasternal long axis M mode during echocardiography.  These data from 
echocardiography and histological analysis show pretreatment with GMCSF-Myo1052 
significantly reduces the incidence of pericardial effusion and myocardial infiltration during 










Figure 3.5 EAM induced by Myosin 1052-1076 in Lewis rats is a T cell mediated disease 
 Passive EAM was induced in Lewis rats by activating myosin primed splenocytes in vitro 
with IL-12 and myosin 1052-1076.  These activated and expanded T cells were injected into 
naïve rats and euthanized on days 14 and 19. Figure 3.6 shows 4 recipient rats euthanized at day 
14 had a maximum histology score of 4 meaning, greater than 25% of myocardium contained 
infiltration.  At day 19, one animal had a score of 3 (10-25% infiltration), while another had a 








Figure 3.6 EAM in the Lewis rat show characteristics of a chronic model 
 
A longitudinal EAM study in Lewis rats was conducted.  EAM was actively induced 
using CFA + myosin 1052-1076 on day 0 and IFA + myosin 1052-1076 on day 7.  Animals were 
euthanized on days 14, 21, 28, and 50.  All hearts were placed in zinc fix for 1 week followed by 
paraffin embedding and staining with H&E.  The longitudinal study revealed 3 rats had histology 











Figure 3.7 Pretreatment with GMCSF-Myo1052 
 
 Figure 3.8 shows the level of myocardial inflammation at day 21 after pretreatment with 
saline, myosin 1052-1076, or GMCSF-Myo1052.  Each symbol represents a single rat.  Of 
animals pretreated with GMCSF-Myo1052, 10 of 14 had no myocardial inflammation, 3 of 14 
had minimal inflammation, and only one animal had medium inflammation.  The saline group 
had a stratification of histology scores, while the myosin 1052-1076 group did display a low 
level of tolerance; however there was no statistical significant difference between the saline and 
myosin 1052-1076 pretreatment groups.  With the exception of a single animal, all rats in the 
GMCSF-Myo1052 pretreatment group had minimal to no infiltration, and pretreatment with the 
fusion protein provided statistically significant protection against EAM compared the PBS and 
Myosin 1052-1076 control groups.  Shaded symbols represent animals with pericardial effusion 
which was observed during echocardiography and was confirmed at euthanasia.  Pretreatment 










Figure 3.8 Lewis rat GMCSF-Myo1052 Pretreatment Histology and Echocardiography 
In (A and C) depict a healthy heart protected against myocarditis by pretreatment with 
GMCSF-Myo1052, while in (B) and (D) a heart from animal pretreated with only saline has 
developed severe infiltration and a pericardial effusion.  In (A) a cross section of a healthy heart 
stained with H&E shows predominately Eosin staining with mostly pink tissue.  In (B) a heart 
with severe EAM is evident as the infiltrating cells pick up the Hematoxylin staining resulting in 
more visible purple.  In (C) echocardiography of a normal heart is shown in parasternal long axis 
view in M mode, while in (D) a heart in the same view with a pericardial effusion.  Note the fluid 
between the pericardial membrane and the myocardium as denoted with red marks.  Also notice 
the thicker walls of left ventricle due to edema.  The green marks in (C) show the anterior and 
posterior walls of the left ventricle beating in phase.  In (D) where an effusion is present the 










3.3 Generation, Expression, and Validation of GMCSF-Myosin 
fusion proteins for BALB/c and A/J mice 
  
 Previous experiments by Blanchfield et al and Abbott et al have revealed GM-CSF based 
cytokine-antigen fusion proteins are potent inhibitors of EAE in rat and mouse models. GM-CSF 
covalently linked to cardiac myosin was also found to attenuate myocarditis in a rat model of 
EAM.  Given the previous success of GM-CSF based cytokine-antigen fusion proteins, GM-
CSF/myosin based fusion proteins were created to study their potential efficacy and mechanisms 
in the treatment of murine EAM.  At minimum, GMCSF-Myosin fusion proteins should provide 
protection against all epitopes represented by the attached myosin antigen domain.  Therefore 
peptides capable of inducing EAM in a given rodent strain are prime candidates for testing 
GMCSF-Myosin fusion proteins.  A literature search revealed myosin 614-629 and myosin 334-
352 were capable of inducing EAM in BALB/c and A/J mice respectively.  The original peptide 
discovered for BALB/c was 614-643 and this extended peptide was used in the BALB/c fusion 
protein to cover all possible epitopes.  These two peptides were chosen to create two GM-CSF 
based fusion proteins.  Both fusion proteins were designed with following sequence, N terminus-
GMCSF-Myosin peptide-histidine tag-C terminus. The HEK 293F expression system was 
chosen instead of the SF-9 insect system to maximize post translation modification compatibility 
with the murine background.  The pIRES2 vector was chosen for its compatibility with the HEK 
293F cell line and because the vector contains a bicistronic reporter molecule, GFP, which can 
be assayed with flow cytometry to assess relative fusion protein production. 
 
 The basic plan to create fusion proteins for both the BALB/c and A/J strains involved 
expanding primer sets containing the appropriate myosin peptide with cytokine and vector 
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overlap which could then be used with an existing pIRES2 GMCSF-neuroantigen construct for 
extension and amplification.  Primers were expanded via PCR in figure 3.9 (A) and (B) to 
generate a 178 bp sequence containing 5’-GMCSF overlap- myosin 614-643-histadine tag-vector 
overlap-3’.  This 178 bp sequence was used with a pIRES2 vector containing GMCSF-PLP178 
to generate GMCSF-Myo614 in figure 3.9 (C).  For the A/J model of EAM a similar approach 
was used to expand primers in figure 3.10 (A) to generate a 146 bp sequence with 5’-GMCSF 
overlap-myosin 334-352-histadine tag-vector overlap-3’.  This 146 bp sequence was then used 
with a pIRES2 vector containing GMCSF-PLP178 to generate GMCSF-Myo334 in figure 3.10 
(B). 
 
Building vectors containing GMCSF-Myo614 and GMCSF-Myo334 
The products from both extension reactions were digested with Dpn I to destroy any 
methylated DNA and Afel I to destroy any GMSCF-PLP178.   These vectors were then used to 
transform top10 E.coli using electroporation.  The transformed bacteria were grown on agar 
plates with Kanamycin.  Single colonies were picked from both plates and grown in 100 µl of 
LB containing Kanamycin for 1 hour.  1 µl of bacteria was harvested from each tube for whole 
cell polymerase chain reaction with vector specific primers.  These products were digested with 
Afel I and Dpn I and run on an agarose gel in figure 13.11 to identify candidate colonies for 
sequencing.  Because PLP178 contains a recognition site for Afel I, digestion of parent template 
vector produced a 535 bp fragment that migrated faster during agarose electrophoresis.  In figure 
3.11 (A) colonies in lanes 1, 3, 4, 5, 6, 8, and 12 were positive for GMCSF-PLP178 because they 
were migrating at the same rate as the 535 bp GMCSF-PLP178 control samples loaded in the 
flanking wells.  In figure 3.12 (A) colonies 2, 7, 9, 10, and 11 were resistant to Afel I, and likely 
contained pIRES2 with GMCSF-Myo614, and were chosen for sequencing.  In figure 3.11 (B), 
59 
 
colonies 1 and 5 contained GMCSF-Myo334 while colonies 2, 3, 4, 6 and 7 were positive for the 
template GMCSF-PLP 178.  Sequencing results in table 13.12 showed clones 1 and 5 contain no 
errors in the region coding for GMCSF-Myo334, while clones 2, 7, 10, 11 contained no errors 
for GMCSF-Myo614.  Ultimately GMCSF-Myo334 clone 1 and GMCSF-Myo614 clone 2 were 
chosen for plasmid midi preparations which were then used to transfect HEK 293F cells.  
 
Transfection and selection of HEK 293 cells with GMCSF-Myo614 and GMCSF-Myo334 
Naïve HEK 293 cells were transfected with plasmid preparations of either GMCSF-
Myo614 clone 2 or GMCSF-Myo334 clone 1 using the Lipofectamine reagent (Life 
Technologies).  The cells were cultured for 48 hours before starting antibiotic selection with 
Geneticin to select only those cells which were transfected with the pIRES2 vector.  Because the 
pIRES2 vector is bicistronic, GFP and the inserted fusion protein are translated from a single 
mRNA transcript.  Therefore GFP expression should mirror fusion protein expression on a cell 
by cell basis.  This allows for the selection of HEK cells producing relatively high quantities of 
GMCSF-Myosin by sorting against GFP fluorescence.  In figure 3.13 (A) and (C) a minimum 




 for HEK cells transfected with GMCSF-
Myo614 and GMCSF-Myo334 respectively.  Cells were then sorted according to this gate and 
checked for purity (the number of cells below the gate criteria after the sort).  Post sort purity 
checks in figure 3.13 (B) and (D) revealed HEK cells transfected with GMCSF-Myo614 and 
GMCSF-Myo334 respectively were greater than 95% pure compared the original gates.  These 






Protein production and purification of GMCSF-Myo614 and GMCSF-Myo334 
Protein production of GMCSF-Myo614 and GMCSF-Myo334 was performed by 
culturing transfected HEK 293F cells in serum free Freestyle Expression media (Invitrogen).  
After approximately 1 to 2 liters of supernatant was harvested from cell culture, the media was 
concentrated to a volume of 20-30 ml prior to nickel column purification.  The histidine tag in 
both GMCSF-Myo614 and GMCSF-Myo334 allow the fusion proteins to bind to a nickel 
column and be eluted by using increasing concentrations of imidazole.  A small amount of each 
elution fraction was run on SDS PAGE to identify purity and the fractions containing the fusion 
protein.   In figure 3.14 (A) significant quantities of GMCSF-Myo614 is present in the fraction 
containing 250 mM imidazole while in (B) GMCSF-Myo334 is also eluting at 250 mM 
imidazole.  Undesired proteins are shown eluting at 60 mM and 100 mM imidazole however 
these proteins are practically nonexistent in the 250 mM fractions.  The 250 mM imidazole 
fractions for each fusion protein were pooled and washed multiple times to reduce the final 
imidazole concentration to less than 1mM.  The washing was done to avoid any in vivo reactions 
from the imidazole. 
 
Validation of the cytokine domain for GMCSF-Myo614 and GMCSF-Myo334 
Bioactivity of cytokine domain for GMCSF-Myo614 and GMCSF-Myo334 was assessed 
by culturing bone marrow cells harvested from the femurs of BALB/c mice with increasing 
concentrations of fusion protein or control unconjugated GM-CSF.  In figure 3.15 cellular 
proliferation of bone marrow cells as measured by [3H]thymidine incorporation shows the C 
terminal addition of myosin 614-643 or myosin 344-352 has no detrimental impact on the 
bioactivity of GM-CSF in the fusion proteins.  These data indicate both fusion proteins should be 




Figure 3.9 GMCSF-Myo614 PCR extension reactions 
For myosin 614-643 three pcr primer expansion reactions were required.  The first 
reaction produced 90 bp fragment shown in (A) that encoded Myosin 614-643. A second pcr 
reaction expanded Myosin 614-643 (90 bp) to include GMCSF overlap on the 5 prime end and 
an 8 residue histidine tag on the 3 prime end (144 bp).  The 144 bp fragment is shown in (B).  









Figure 3.10 GMCSF-Myo334 polymerase chain reaction extension reactions 
For the A/J fusion protein the first polymerase chain reaction produced a 111 bp 
fragment, shown in (A), encoding the myosin 334-352 peptide with GM-CSF overlap on the 5 
prime end and an 8 residue histidine tag on the 3 prime end.  A second reaction expanded the 111 








Figure 3.11 Identifying colonies with GMCSF-Myo614 and GMCSF-Myo334 
Whole cell PCR reactions using pIRES2 vector specific primers were setup from single 
colonies on Kanamycin plates following electroporation.  After whole cell PCR reactions were 
complete, digestion with Afel I was performed to discriminate between GMCSF-Myosin or 
GMCSF-PLP (template).  Colonies containing GMCSF-PLP contain a recognition site for Afel I 
and are reduced to a 535 bp fragment that migrates faster in agarose gel compared to GMCF-
Myosin.  In (A) colonies 2, 7, 9, 10, and 11 were identified as containing GMCSF-Myo614.  In 
































Figure 3.13 Establishing gates for GFP high cells transfected with fusion proteins and 
checking post sort purity 
HEK 293F cells transfected with either GMCSF-Myo614 or GMCSF-Myo334 were 
sorted to select cells producing relatively high amount of fusion protein.  Using the 488 nm laser 
and measuring emission at 509 nm a gate was established in Figure 3.14 to select only cells with 
high GFP production.  In figure 3.14, the boxes present in the upper half of (A) and (C) were 
established for cells transfected with GMCSF-Myo614 and GMCSF-Myo334 respectively. After 
sorting the cells, their fluorescent intensity at 509 nm was measured again, and confirmed that 
95% of cells with GMCSF-Myo614 (B) and 96% of cells with GMCSF-Myo334 (D) had GFP 


























Figure 3.14 Expression and Purification of GMCSF-Myosin fusion proteins for BALB/c 
and A/J mice 
 Figure 3.16 (A) shows the elution of GMCSF-Myo614 (20,355 kDa) at 100 mM and 
250mM of imidazole while figure 3.16 (B) shows the elution of GMCSF-Myo334 (19,427 kDa) 
at 100mM and 250mM.  The multiple bands of GMCSF-Myo334 are likely due to differences in 
post translation modification.  The purity of each fusion protein preparation was estimated by 
comparing the intensity of contaminating bands to the intensity of the bands representing the 
























Figure 3.15 Validation of GMCSF-Myosin fusion proteins for BALB/c and A/J mice 
Bioactivity of the cytokine domains of GMCSF-Myo614 and GMCSF-Myo334 were 
verified by culturing bone marrow cells with increasing concentrations of fusion protein or 
unconjugated GM-CSF.  Bone marrow cells were cultured with GMCSF-Myo614, GMCSF-
Myo334 or GM-CSF in full log dilutions from one femptomolar to one nanomolar.  All 
concentrations were present in triplicate to assess variability.  On day 2 all cells were pulsed with 
[3H]thymidine and on day 3 all cells were harvested for [3H]thymidine counts.  Both fusion 
proteins as well as unconjugated GM-CSF induced a rapid increase in bone marrow proliferation 
















3.4 Testing the Efficacy of GMCSF-Myo614 in the BALB/c model of 
EAM 
Pretreatment and treatment experiments with GMCSF-Myo614 were conducted to 
explore the hypothesis that GMCSF-Myo614 could alter the myosin 614 CD4
+
 T cell repertoire 
and prevent or inhibit EAM in BALB/c mice.  In figure 3.16 two pretreatment experiments have 
been combined into one graph.  Mice received either saline, myosin 614-629 or GMCSF-
Myo614 on days -21, -14, and -7 prior to active EAM induction on day 0.  The data in figure 
3.18 demonstrate mice receiving GMCSF-Myo614 prior to EAM induction with myosin 614-629 
are well protected against myocardial inflammation.   A one way ANOVA analysis with a 
Bonferroni post hoc test revealed statistical significant differences between the fusion protein 
group and either control group.  To further assess the ability of GMCSF-Myo614 to inhibit 
EAM, a treatment experiment was conducted and is shown in figure 3.17.   Mice were subjected 
to active EAM induction on day 0 with myosin 614-629.  Mice were assigned to one of four 
treatment groups receiving either saline, myosin 614-629, GMCSF-Myo334 or GMCSF-Myo614 
on days 10, 12, 14 and 16.  On day 28 all mice were euthanized and their hearts were collected 
for histological analysis as previously described.  Statistical significance was not reached when 
comparing the severity of inflammation in the GMCSF-Myo614 group to the control groups.  
The pretreatment experiments demonstrate GMCSF-Myo614 has the ability to inhibit myosin 
614 induced EAM in BALB/c mice.  Table 3.18 shows summary statistics for all GMCSF-








Figure 3.16 Pretreatment with GMCSF-Myo614 in the BALB/c model of EAM  
 BALB/c mice were given either PBS, 2 nanomoles of Myosin 614-629, or 2 nanomoles 
of GMCSF-Myo614 on days -21, -14 and -7 prior to EAM induction on day 0 and day 7 with 
CFA + Myosin 614-629.  All animals were euthanized on day 21 to collect hearts for histological 
analysis with H&E staining.  Animals pretreated with PBS, Myosin, or GMCSF- Myo614 had 
average histology scores of 2.0, 3.0, and 0.17 respectively.  Pretreatment with GMCSF-Myo614 
significantly blocked or attenuated myocardial infiltration when EAM was induced with Myosin 
















Figure 3.17 GMCSF-Myo614 treatment after EAM induction 
Previous experiments showed that GMCSF-Myo614 and GMCSF-Myo1052 inhibited 
EAM when given as a pretreatment before EAM induction.  The current experiment was 
conducted to evaluate the efficacy of GMCSF-Myo614 when given after EAM induction.  All 
animals received myosin 614-629 emulsified in CFA on days 0 and 7.  On days 10, 12, 14, and 
16 animals received either saline, myosin 614-629, GMCSF-Myo334 or GMCSF-Myo614 
according to their respective group assignments.  Upon euthanasia all hearts were placed in zinc 
fix.  The hearts were paraffin embedded, stained with H&E, and scored for infiltration as 
previously described.  The level of myocardial infiltration in the GMCSF-Myo614 treatment 































3.5 EAM on the C57BL/6 Background 
 
Current EAM studies in mice are not conducted in the C57BL/6 strain.  Acute 
myocarditis can be induced in C67BL/6 mice with coxsackie virus, however this model does not 
appear to be a self-sustaining autoimmune version of myocarditis.  Due to the majority of 
knockout mice being maintained on the C57BL/6 background, EAM studies exploring genetic 
mechanisms using knockout mice are time consuming and expensive.  Normally the knockout of 
choice on the C57BL/6 background must be back crossed to an EAM susceptible background 
such as BALB/c or A/J mice.  In an effort to discover a myosin peptide capable of inducing 
EAM in C57BL/6 mice, the cardiac alpha myosin heavy chain was queried against the H2-I-A
b
 
haplotype, the murine MHC II equivalent allele found in C57BL/6 mice.  The search produced a 
cluster of hits ranging from 718 to 737 in figure 3.19.  Two candidate peptides were chosen, 
myosin 718-736 and myosin 721-735.  Previous EAM experiments in BALB/c mice and 
previous EAE experiments in C57BL/6 mice have shown Interferon gamma knockout mice or 
Interferon gamma receptor knockout mice develop a much more severe form of their respective 
autoimmune diseases [61, 62].  Enhanced autoimmune disease has also been found in C57BL/6 
which are void of B cells [63].   
Because the C57BL/6 background is notoriously difficult to induce EAM, Ifngr1 
-/-
 mice 
and B cell deficient mice were included with wildtype mice for the first attempt to induce EAM 
with the new myosin candidates.  Myosin 718-736 was emulsified in CFA and injected on day 0 
and day 7.  On day 0 the mice were also injected with pertussis toxin IP.  On day 21 all animals 
were euthanized to collect hearts.  Upon opening the chest, the hearts of the Ifngr1 
-/-
 mice 
displayed severe lesions over the entire heart.  The lesions appeared to be similar to those 
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sometimes seen in the Lewis rat model of EAM.  In figure 3.20 (A) and (B), histological analysis 
with H&E staining confirmed 9 of 11 Ifngr1 
-/-
  mice had severe level 4 (>25%) infiltration.  
C57BL/6 wild type mice in figure 3.20 (A) and B cell deficient mice in (B) were mostly resistant 
to EAM with myosin 718-736.  Representative H&E images and echocardiography from Ifngr1 
-
/-
 mice and wildtype C57BL/6 mice, immunized with myosin 718-736, are shown in figure 3.21.   
In figure 3.21 (B) greater than 75% of cross section of the heart is infiltrated with leukocytes.  In 
figure 3.21 (D), the edema is so severe the lumen of the left ventricle has been significantly 
reduced which would affect cardiac output. Unaffected hearts from C57BL/6 wildtype mice are 
shown in figure 3.22 with histology (A) and echocardiography (C).   
The second myosin peptide candidate, myosin 721-735 was tested using male and female         
Ifngr1 
-/-
 mice, B cell deficient mice, and C57BL/6 wild type mice.  In figure 3.22 both B cell 
deficient mice and C57BL/6 wildtype mice are resistant to myosin 721-735 induced EAM. 
Severe disease was observed in the two male Ifngr1 
-/-
 mice, while little to no infiltration was 
found in the female Ifngr1 
-/-
 mice.  Splenocyte activation data in figure 3.23 supports the 
hypothesis that myosin 718-736 is more potent for inducing EAM compared to myosin 721-735.  
In figure 3.23 splenocytes were collected from two Ifngr1 
-/-
 mice primed with CFA+ myosin 
718-736.  These splenocytes were subsequently activated in vitro with myosin 718-736 and 
myosin 721-735 as well as two additional control peptides.  The data show myosin 721-735 
cannot activate the full repertoire of T cells created from the myosin 718-736 priming compared 
to myosin 718-736. 
An experiment was conducted to ascertain if Myosin 718-736 could induce EAM in mice 
deficient in inducible nitric oxide synthase 2 (iNOS2 
-/-
).  Previous EAE experiments in C57BL/6 
mice have indicated IFN-γ mediated nitric oxide is a critical signaling responsible for apoptotic 
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control of antigen specific activated T cells [64].   The working hypothesis was with inducible 
nitric oxide eliminated myosin specific T cells would experience less apoptosis and may survive 
long enough to cause EAM in C57BL/6 mice.  The data in figure 3.24 indicate nitric oxide from 
inducible nitric oxide synthase 2 is not by itself responsible for the inhibition of myosin 718-736 






















Figure 3.19 Selecting candidate peptides from the cardiac myosin heavy chain to induce 
EAM on the C57BL/6 background.   
The alpha cardiac myosin heavy chain was selected to search for peptide epitopes capable 
of inducing EAM in mice on the C57BL/6 background.  The website: 
http://tools.immuneepitope.org/mhcii/ was chosen.  The murine alpha cardiac myosin heavy 
chain protein sequence was obtained from PubMed accession number: AAA37162. The 
algorithm selected a number of overlapping predicted sequences from the alpha cardiac myosin 
heavy chain predicted to have high affinity for the H2-I-A
b
 MHC II allele.  The lower the 
percentile rank the more likely a peptide sequence is predicted to be displayed by the selected 
haplotype.  Myosin 718-736 and myosin 721-735 were chosen as candidate peptides to induce 


































Figure 3.20 EAM in on the C57BL/6 background using Myosin 718-736 
Two CFA + myosin 718-736 injections on days 0 and 7 resulted in severe EAM in Ifngr1 
-/-
 mice (A) and (B).  Most Ifngr1 
-/-
 mice developed severe myocarditis with multiple lesions 
present on the outside of the heart and greater 50% infiltration in H&E cross sections.  C57BL/6 
wildtype mice (A) and B cell deficient mice (B) were generally resistant to myosin 718-736 
induced EAM.  In (B), groups labeled without 718 received emulsions containing saline and 




























Figure 3.21  Histology and echocardiography of EAM in Ifngr1 
-/- 
mice using myosin 718-
736 
H&E stained hearts from a wildtype C57BL/6 mouse (A) and an Ifngr1 
-/-
 mouse (B) after 
EAM induction with myosin 718-736.  In (C) and (D) normal hearts and EAM affected hearts 
with severe edema respectively are shown using the parasternal long axis view with M mode 
during echocardiography.  One would expect decreased cardiac output due to edema reducing the 
size of the left ventricular lumen.  Indeed some Ifngr1 
-/-
 mice with severe EAM experienced 
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Figure 3.22  EAM using myosin 721-735 
EAM induction using the shorter peptide candidate was also conducted on the C57BL/6 
background using wildtype mice, Ifngr1 
-/-
 mice and Ighm 
-/- 
mice.  The mice were injected with 
200 µg of myosin 721-735 emulsifed in 50 µl of CFA and 50 µl of saline on days 0 and 7. The 
mice were also IP injected with pertussis toxin on day 0.  All mice were euthanized on day 21 
and hearts were  placed in zinc fix for one week prior to paraffin embedding.  Slides were stained 
with H&E and myocardtis was assessed on a scale of 0 to 4 as previously described.  Wildtype 
and B cell knockout mice were resistant to myosin 721-735 induced EAM.  Ifngr1 
-/-
 male mice 
developed full EAM to myosin 721-735 while female Ifngr1 
-/-
 mice displayed little to no 






















Figure 3.23 Activation of splenocytes from animals primed with Myosin 718-736 
Two female Ifngr1 
-/-
 mice were each injected with 200 µg of myosin 718-736 emulsified 
in 0.05 ml of saline and 0.05 ml of CFA on days 0 and 7.  On day 14 the mice were euthanized 
and their spleens were harvested.  The spleens were processed into a single cell suspension.  
Approximately 250,000 splenocytes were cultured in each well of a 96 well plate with various 
myosin peptides known to cause EAM in BALB/c mice, C57BL/6 mice and Lewis rats.  Each 
concentration of each peptide was cultured in triplicate.  The cells were pulsed with 
[3H]thymidine and harvested to assess T cell activation.  The results show significant T cell 
activation in the presence of myosin 718-736 as expected.  Myosin 721-735 displayed reduced T 
cell activation while the remaining control peptides, myosin 614-629 and myosin 1052-1076, 
induced no cell growth greater than background.  The splenocyte activation data is consistent 





























Figure 3.24 Exploring nitric oxide inhibition of EAM in C57BL/6 mice 
Three Ifngr1 
-/-
 mice and four iNOS2
-/-
 mice were injected with 200 µg of myosin 718-
736 emulsified in 0.05 ml of saline and 0.05 ml of CFA on days 0 and 7.  On day 21 all mice 
were euthanized to collect hearts for histological analysis.  All hearts were zinc fixed, paraffin 
embedded, stained with H&E and scored from 0 to 4 as previously described.  The positive 
control Ifngr1 
-/-
 mice displayed severe EAM while the iNOS2
-/-
 mice had no myocardial 
infiltration.  This experiment suggests nitric oxide by itself is not sufficient to inhibit antigen 












   
 
Discussion 
4.1 Significance of GMCSF-Myosin proteins 
The primary purpose for creating GMCSF-Myosin fusion proteins was to assess their 
tolerogenic activity in the Lewis rat and BALB/c models of EAM.  Previous studies have shown 
cytokine antigen fusion proteins using GM-CSF, Interferon-β, Interleukin (IL)-2, or IL-16 fused 
to a myelin autoantigen were capable of blocking progression of EAE [54-56, 58, 59].  GM-CSF 
based fusion proteins were found to be the most potent for inhibiting EAE compared to 
Interferon-β, Interleukin (IL)-2, or IL-16.   It was therefore hypothesized GMCSF-Myosin based 
fusion proteins could achieve the significant tolerogenic activity in rodent models of EAM.  The 
current study demonstrates for the first time that GM-CSF fused to a myocarditic antigen from 
the cardiac myosin heavy chain is capable of preventing myocarditis in the Lewis rat and 
BALB/c models of EAM, and provides evidence that GM-CSF fusion proteins can prevent 
autoimmune diseases other than EAE.   
  Several significant differences in EAE and EAM provide different challenges for 
tolerogenic vaccines.  Previous GM-CSF fusion proteins have provided tolerance in rodent 
models of EAE to myelin basic protein, myelin oligodendrocyte glycoprotein, and proteolipid 
protein, all of which are proteins nervous system.  The cardiac myosin heavy chain, in contrast, 
is contractile protein inside the membrane of cardiac muscle cells.  Therefore, GMCSF-Myosin 
fusion proteins are the first GM-CSF fusion proteins in which the antigen domain is derived from 
a cardiac protein.  Previous GMCSF-antigen fusion proteins have inhibited EAE, where 
significant inflammation occurs behind the blood brain barrier in the central nervous system.  
GMCSF-Myo1052 and GMCSF-614 are the first known fusion proteins to inhibit autoimmune 
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disease with a target organ in the periphery, not inside the blood brain barrier.  Previous 
GMCSF-antigen fusion proteins have been used in mice on the C57BL/6 and SJL backgrounds 
due to their mainstream use in EAE models. Mice on the BALB/c and A/J background are the 
primary choice for EAM research, and GMCSF-Myo614 is first GMCSF-antigen fusion protein 
known to inhibit autoimmune disease in BALB/c mice. 
 
Mechanistically GMCSF-Myosin fusion proteins appear to be targeting APCs through the 
cytokine domain.  Figure 3.3 shows significantly higher proliferation of myosin 1052-1076 T 
cells from GMCSF-Myo1052 at lower concentrations compared to free peptide.  This indicates 
the cytokine portion of the fusion protein is enhancing uptake through receptor mediated binding 
with subsequent presentation of the antigen domain.  Choosing an appropriate peptide from the 
protein of interest is also crucial for successful tolerance.  GMCSF-Myo334 is similar to 
GMCSF-Myo614 with exception of the antigen domain.  Both fusion proteins have two n-linked 
glycosylation sites.  In figure 3.14 (B) GMCSF-Myo334 has three distinct bands while in figure 
3.14 (A) GMCSF-Myo614 has only one band.  A possible explanation is that HEK cells 
producing GMCSF-Myo334 were overwhelmed with the amount of fusion protein being 
translated and could not glycosylate all the fusion protein before excretion.  Like myosin 614-
629, myosin 334-352 is derived from the alpha cardiac myosin heavy chain.  However while 
myosin 334-352 can be presented in mice with the H2-I-A
a
 class II allele, such as A/J mice, 
myosin 334-352 cannot be presented in mice with the H2-I-A
d
 allele such as BALB/c mice.  
BALB/c mice possess the H2-I-A
d
 haplotype and can present myosin 614-629 but not myosin 
334-352.   Higher disease incidence in BALB/c mice pretreated with GMCSF-Myo334 
compared to pretreatment with GMCSF-Myo614 indicates the antigen domain of the fusion 
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protein must not only be derived from the appropriate target organ but must also be  presented on 
MHC II of the recipient.  Reduced disease incidence in mice treated with GMCSF-Myo614 
versus GMCSF-Myo334 also indicates antibodies against GM-CSF are not a likely mechanism 
for tolerance.  If anti-GMCSF antibodies were responsible for the tolerance from GMCSF-
Myosin one would expect similar results from GMCSF-Myo614 and GMCSF-Myo334.   
It would be interesting to perform a longitudinal study with GMCSF-Myo1052 in Lewis 
rats given the chronic disease observed in figure 3.6.  Historically EAM in the Lewis rats is 
referred to as a relatively acute model, with disease peaking at day 21 and a gradual decline 
thereafter.  However, figure 3.6 clearly demonstrates some percentage of Lewis rats are capable 
of sustained myocardial inflammation at day 50 during EAM.  Whether the decrease in disease 
severity at day 28 is indicative of relapsing disease or just reflects the small number of animals is 












4.2 GMCSF-ANTIGEN FUSION PROTEINS AND T CELL 
MEDIATED AUTOIMMUNE DISEASE 
  
 It is highly likely GMCSF-Myosin fusion proteins are providing tolerance against EAM 
by altering cardiac myosin specific CD4
+
 T cells. Studies have demonstrated disease in both the 
Lewis rat and the BALB/c model of EAM are dependent on CD4
+
 T cells for disease.  In both 
the BALB/c and Lewis Rat models of EAM CD4
+
 T cells that recognize the myosin 614-629 and 
myosin 1052-1076 epitopes respectively, have been shown capable and sufficient to induce 
EAM through adoptive transfer experiments.  Previous adoptive transfer experiments have 
demonstrated myosin 1052-1076 specific CD4
+
 T cells and myosin 614-629 specific CD4
+
 T 
cells are sufficient for inducing autoimmune myocarditis in their respective models.  Any 
successful inhibition of EAM in the BALB/c and Lewis rat models of EAM would logically have 
to inhibit these myosin specific CD4
+
 T cells.  Figure 3.3 demonstrates GMCSF-Myo1052 is 
capable of stimulating myosin specific T cells in the presence of antigen and irradiated APCs.  
Moreover, antibody inhibited proliferation of myosin 1052-1076 T specific cells through anti-
MHC II or anti-CD4 in figure 3.4 provide evidence that GMCSF-Myo1052 is altering the CD4
+
 
T cell repertoire.  The partial inhibition of myosin 1052-1076 T cells with anti CD4 is consistent 
with previous experiments demonstrating CD4 stabilizes and enhances the MHC II/peptide T cell 
receptor binding, but is not absolutely required for MHC II antigen presentation.  The complete 
blockage of MHC II antigen presentation in the presence of anti MHC II indicates the antibody is 
directly preventing the T cell receptor of myosin 1052-1076 T cells from engaging with APCs.  
Figure 3.3 demonstrates GMCSF-Myo1052 has stimulatory effects in vitro on myosin specific 
CD4
+
 T cells that are likely Th1 memory cells.  However its effects in vivo appear to be 
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inhibitory as seen in pretreatment experiments in figures 3.7 and 3.16.  This paradox might be 
explained by differences in APCs present in the subcutaneous compartment versus APCs derived 
from the spleen and maintained in culture. The OX6 and W3/25 antibody inhibition experiments 
suggest MHC II presentation is fundamental mechanism of GMCSF-Myo1052 whether it is 




















4.3 GMCSF-MYOSIN FUSION PROTEINS: TOLERANCE 
VERSUS IMMUNITY 
 
Evidence for pro-inflammatory effects mediated by GMCSF-Myosin 
 GM-CSF is a key cytokine involved in the differentiation and maturation of myeloid 
leukocytes including macrophages and dendritic cells [65, 66].  Multiple studies in EAE and 
EAM indicate a pro-inflammatory role for GM-CSF in EAE and EAM.  In the Lewis rat model 
of EAM, GM-CSF mRNA levels in heart lesions have been found to be elevated on days 14, 21, 
28, 35, and 42 post EAM induction and correlated with disease severity [67].  GM-CSF 
-/-
 mice 
have been shown to be resistant to EAE and EAM induction [68, 69].  Moreover adoptive 
transfer experiments using GM-CSF
-/-
 donor mice have demonstrated antigen specific CD4
+
 T 
cells to be the source of GM-CSF required for EAE and EAM [69-71].   
 In EAE and EAM, GM-CSF produced by antigen specific T cells has been shown to have 
a profound effect on antigen presenting cells, including dendritic cells and macrophages.  GM-
CSF produced by encephalitogenic T cells has been shown to increase cell surface expression of 
MHC II, CD80, and CD40 on microglial cells [71].  Furthermore EAE was restored in mice with 
GM-CSF 
-/-
 T cells by injecting LPS directly into the CNS, indicating GM-CSF plays a critical 
role in EAE by activating APCs [71].  Other data has shown GM-CSF dependent CD103+ 
dermal dendritic cells can induce severe EAE and stimulate naïve T cells to produce IFN-γ and 
IL-17 [72].  Given that IFN-γ and IL-17 have been notably increased in both models of EAE and 
EAM it is likely both Th subsets are contributing to disease.  
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It is conceivable that GMCSF-antigen fusion proteins are activating APCs which then 
increase IFN-γ to concentrations high enough for self-regulating effects.  Several studies indicate 
that IFN-γ can mediate apoptosis of CD4+ T cells [62, 73, 74].  In EAE specifically it has been 
observed that IFN-γ mediated production of indoleamine 2,3 dioxygenase (IDO) by DCs lead to 
T cell apoptosis and suppression of disease [75, 76].  It also possible IDO produced by activated 
APCs can inhibit EAE by increasing regulatory T cells [77].  Another study found IFN-γ plays a 
critical role in the induction of T regulatory cells that limit EAE [78].  Other data suggests the 
Th1:Th17 ratio may play a role in number of neutrophils in the CNS during EAE and effect 
disease severity [74].  The studies above indicate numerous possible pathways for IFN-γ to 
regulate or inhibit EAE.  Exacerbated disease observed in IFN-γ 
-/- 
mice in both EAE and EAM 
further indicate a regulatory role for IFN-γ [61, 79-82].  As GM-CSF activated APCs can 
produce IL-12 which then drive production of IFN-γ, it is possible GMCSF-antigen fusion 
proteins are accelerating this pathway and providing tolerance indirectly via IFN-γ.   
Published data investigating the mechanisms of GMCSF-NAg fusion proteins support an 
IFN-γ mediated pro-inflammatory hypothesis.  GMCSF-MOG35-55 has been shown to inhibit 
EAE when delivered adjacent to CFA-MOG35-55 emulsions and when added directly to CFA-
MOG 35-55 emulsions [50].  Furthermore it has been demonstrated in vitro that GMCSF-MOG35-
55 can differentiate and expand inflammatory dendritic cells, which when stimulated with IFN-γ 
can inhibit MOG specific T cells through the secretion of nitric oxide [50].  It is therefore 
possible the inhibition of EAM observed in Figure 3.17, when GMCSF-Myo614 was 
administered after disease induction, was due in part to GMCSF-Myo614 derived inflammatory 
dendritic cells responding to IFN-γ by the secretion of nitric oxide thereby inhibiting myosin 
614-629 specific T cells and preventing EAM. 
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Evidence for tolerance mediated by GMCSF-Myosin 
 Dendritic cells are considered professional antigen presenting cells due to their native 
ability to present antigens via MHC II.  However, the context in which these antigens are 
presented can have a profound effect on how the immune system responds to the presented 
antigen in question.   Dendritic cells in an immature state express low levels of MHC II and 
costimulatory molecules such CD80/86 [83].  Antigen presentation without co-stimulation by 
immature DCs can result in T cell anergy [84].  Studies have also shown semi-mature DCs can 
also support tolerance by increasing expression of MHC II, CD 80/86, and tolerogenic cytokines 
such IL-10 but not pro-inflammatory cytokines such IL-12 and IL-6 [83, 85].  In a non-
inflammatory environment, GM-CSF and cytokines such as TGF-beta will result in immature 
and semi-mature DCs that favor tolerance.   
 Abundant evidence supports the concept that semi-mature DCs provide tolerance by 








 T cells have been 
extensively studied and found capable of suppressing or inhibiting effector T cells through 
inhibitory cytokines, cytolysis, metabolic disruption, and by fostering tolerogenic phenotypes in 
APCs [86].  Multiple studies in models of experimental autoimmune thyroiditis, experimental 
autoimmune myasthenia gravis, and experimental type 1 diabetes have demonstrated treatment 
with GM-CSF before and after disease induction suppresses disease via semi-mature DCs that 
increase antigen specific IL-10 secreting T regulatory cells [87-92].  Experiments by Prabhakar 




) are the 
subset of GM-CSF derived DCs responsible for tolerance [92, 93].  It has also been shown, that 
dendritic cells derived from bone marrow cells using GM-CSF are capable of expanding natural 
T regulatory cells and adaptive T regulatory cells in vitro by T cell receptor independent and T 
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cell receptor dependent mechanisms respectively [94].   Previous experiments, in which GM-
CSF was injected in vivo, indicated tolerogenic DCs were providing efficacy by expanding 
antigen specific T regulatory cells.  To further confirm this theory, multiple experiments were 
conducted in which in vitro derived tolerogenic DCs were pulsed with antigen, relevant to the 
disease model, prior to in vivo administration [95-97].   Specifically in EAE, MOG35-55 pulsed 
dendritic cells were shown to inhibit EAE in C57BL/6 mice while DCs not pulsed provided no 
protection [98].  In EAM, DCs pulsed with myosin 614-629 were found to inhibit disease while 
DCs pulsed with type II collagen provided no protection [99].  Given the abundant evidence that 
semi-mature DCs can induce tolerance through antigen specific T regulatory cells, and that this 
mechanism has been confirmed in same models of EAE and EAM with exact same antigens used 
in GMCSF-MOG35-55 and GMCSF-Myo614, is not unreasonable to speculate that GMCSF-
myosin antigen fusion proteins are mediating protection in part, by binding to monocytes 
inducing their differentiation into semi-mature DCs while also providing the appropriate antigen 
for MHC II presentation and subsequent expansion of antigen specific T regulatory cells.  
 Although regulatory T cells specific for the antigen domain of GMCSF-Myosin are 
powerful in their own right, it is plausible their suppression is greatly amplified by infectious 
tolerance.  Numerous studies provide evidence that T regulatory cells are  key players in the 
phenomenon of infectious tolerance [100].  At its most simple definition, infectious tolerance 
occurs when a regulatory T cell specific to antigen “A” confers a regulatory phenotype to a naïve 
or effector T cell specific for different antigen “B”.  In this regard infectious tolerance is 
powerful immune modulator that is thought to play a major role in preventing autoimmunity.  
One model of infectious tolerance involves a regulatory T cell acting directly on a naïve or 
effector T cell.  This interaction may occur when both cells are bound to a common APC that is 
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not directly responsible.  Evidence for this model comes from experiments where TGF-β derived 
from T regulatory cells was found to convert effector T cells into suppressive Foxp3
+
 T cells 
[101].  IL-10 produced by T regulatory cells has been shown to convert effector T cells into 
suppressive T cells [102, 103].  It has also been shown that Foxp3
+
 T regulatory cells can 
respond to IL-10 by making more IL-10 in positive feedback loop [104].  A third cytokine 
produced by T regulatory cells that could mediate infectious tolerance is IL-35 [105].  It has been 
shown that IL-35 from T regulatory cells can convert effector CD4
+
 T cells into class of 
suppressive T cells that do not express Foxp3 yet can still mediate tolerance through IL-35 [105].  
It is therefore possible that if GMCSF-Myosin fusion proteins are creating tolerogenic APCs that 
express multiple antigens from cardiac proteins, they would create an environment where 
regulatory T cells, could convert nearby effector T cells, on the same APC, to a suppressive 
phenotype through TGF-β, IL-10, or IL-35. 
 In addition to providing an environment that fosters proximity between T regulatory cells 
and effector cells, APCs such as dendritic cells may play an active role in creating T cells with 
suppressive function.  CD8
+
 splenic DCs are potent inducers of T regulatory cells when TFG-β is 
available [106].  IL-10 producing DCs generated in vitro with GM-CSF, IL-4 and IL-10 have 
also been found capable of converting effector T cells into IL-10 secreting suppressive T cells 
[107, 108].  It is therefore conceivable during the pretreatment experiments GMCSF-Myosin was 
upregulating IL-10
+
 DCs expressing the myosin domain.  If these GMCSF-Myosin induced IL-
10
+
 DCs also expressed other cardiac antigens from normal turn-over they could in theory 
convert effector cardiac autoreactive T cells into T regulatory cells.  If IL-10 is being produced 
by GMCSF-Myosin induced DCs as well as T regulatory cells that respond to IL-10 in a feed 
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forward loop, it is possible reciprocal exchange of cytokines such IL-10 may serve to amplify 
infectious tolerance to prevent autoimmune myocarditis.        
 
Variables that could determine tolerance or immunity from GMCSF-Myosin 
 Evidence for micro environmental effects of GM-CSF on DCs in EAM come from two 
key studies.  One study demonstrated that bone marrow derived dendritic cells, created using 
GM-CSF, LPS, and anti CD40 are capable of inducing EAM when pulsed with myosin 614-629 
and adoptive transferred into naïve BALB/c recipient mice [10].  A seemingly contradictory 
study found bone marrow derived dendritic cells cultured with TNF-alpha, IL-4 and pulsed with 
cardiac myosin are capable of preventing EAM in BALB/c mice [99].  The important note here 
is the way in which the dendritic cells were created.  The pro-inflammatory experiment used 
GM-CSF, LPS, and anti CD40 to induce the dendritic cells into a fully mature state and acquire 
an inflammatory phenotype capable of supporting Th1 effector cells.  The tolerogenic 
experiment used GM-CSF, TNF-alpha, and IL-4 to create dendritic cells with relatively lower 
levels of MHC II, CD80, CD86, IL-12p70, and IL-23.  GM-CSF is common to both experiments 
but other growth factors included in the generation of the dendritic cells had a profound effect on 
the outcome.  It is therefore possible the inhibition of EAM observed during fusion protein 
pretreatment and treatment are due to different mechanisms in which tolerogenic or 
inflammatory DCs respectively, are modulating the antigen specific T cell repertoire via different 
but not mutually exclusive mechanisms.  
 GM-CSF concentration is a factor that could affect the balance between inflammatory 
versus tolerogenic responses.  Lower levels of GM-CSF favor immature tolerogenic DCs while 
higher concentrations promote inflammatory DCs [109].  In EAM specifically it has been 
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observed that using 1 millon tolerogenic DCs pulsed with myosin can provide tolerance while 2 
million cells actually enhanced disease [99].  This suggests the concentration of GM-CSF in 
addition to other stimuli present can impact tolerance versus inflammation. It is possible the dose 
of GMCSF-Myosin used could have a significant effect on tolerance versus inflammation.  
However EAE experiments have demonstrated higher doses of GMCSF-neuroantigen fusion 
proteins provide more tolerance.  It is therefore likely higher doses of GMCSF-Myosin will 

















4.4 THE IMPLICATIONS OF GMCSF-ANTIGEN FUSION 
PROTEINS FOR CLINICAL MYOCARDITIS 
 
GMCSF-Myosin and HLA alleles 
GMCSF-Myosin fusion proteins have demonstrated repeatable success in murine models 
of experimental autoimmune myocarditis.  These experiments were possible because specific 
myocarditic epitopes are known in Lewis rats and BALB/c mice.  For successful treatment of 
autoimmune myocarditis with GMCSF-antigen fusion proteins, specific major myocarditic 
epitopes will need to be identified in the human population.  The epitopes will depend on the 
MHC II haplotype of each individual.  Because the MHC II genes are some of the most 
polymorphic in our genome, identifying myocarditic epitopes will be a significant task. 
  Preliminary studies have identified certain MHC II haplotypes with possible 
associations to myocarditis or inflammatory idiopathic cardiomyopathy.  A significant 
association was found between HLA DQB1*0303 and patients with myocarditis. Other studies 
have found associations between idiopathic dilated cardiomyopathy and the following HLA 
alleles: HLA-DR4, HLA-DR5, HLA-DQA1∗0501, and HLA-DQB1∗0303.  These haplotypes 
could serve as starting points for identifying myocarditic epitopes in the human population. The 
algorithm used at http://tools.immuneepitope.org/mhcii/  maybe of some help given the extensive 
list of human MHC II haplotypes it supports.  If future studies confirm elevated CD4
+
 T cells 
that recognize cardiac antigens when presented by APCs with the afore mentioned alleles or 
other HLA-DP, HLA-DQ, or HLA-DR alleles in patients with chronic myocarditis, it would 




 Progress towards a GMCSF-Myosin fusion protein to prevent myocarditis and 
cardiomyopathy in type 1 diabetic patients may be underway.  Many type 1 diabetic patients 
have the HLA-DQ8 allele, and experience excessive morbidity due cardiovascular disease and 
complications following a myocardial infarction. Evidence for an autoimmune etiology to this 
excessive morbidity comes from a murine animal model.  Transgenic non-obese diabetic mice 
were altered with murine CD4 and H2 genes knocked out, and human CD4 and HLA-DQ8 
inserted.  It was soon discovered HLA-DQ8 mice spontaneously developed myocarditis and 
cardiomyopathy.  Additional experiments revealed the myocarditis was lymphocyte mediated 
and not humoral dependent.  When HLA-DQ8 was queried against the murine cardiac alpha 
myosin heavy chain on http://tools.immuneepitope.org/mhcii/, three unique regions were 
identified with high affinity for HLA-DQ8.  One of these epitopes was myosin 334-352.  
Interestingly, this is a known myocarditic epitope capable of inducing autoimmune disease in A/J 
mice which possess the murine H2-I-A
a
.  The cytokine bioactivity of GMCSF-Myo334 has 
already been confirmed figure 3.15.  In figure 3.17, GMCSF-Myo334 was included as a control 
and failed to provide protection against EAM in BALB/c as expected due to differences in H2 
alleles between BALB/c and A/J mice.  It remains to be seen if myosin 334-352 is truly a 
myocarditic epitope in NOD HLA-DQ8 mice, and if so could treatment with GMCSF-Myo334 
prevent the spontaneous myocarditis associated with this strain.  
 
The Need for antigen specific therapy to treat myocarditis 
 To date this is first known example of a therapeutic that can affect progression of 
experimental autoimmune myocarditis via inhibition of the immune system in an antigen specific 
manner without using in vitro derived cells.  The only previous known therapeutic approach 
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capable of inhibiting EAM in an antigen specific manner utilized bone marrow derived dendritic 
cells pulsed with myosin 614-629 [99].  While this approach is promising, therapeutics using 
clinical administration of in vitro cultured cells are more expensive and more difficult to 
standardize compared to traditional drugs and biologics including fusion proteins.  In addition, 
GMCSF-Myosin fusion proteins may be providing inhibition of EAM through inflammatory and 
tolerogenic mechanisms.  To date antigen pulsed DCs appear to be providing inhibition of EAM 
exclusively through tolerogenic mechanisms.  
 
GMCSF-Myosin fusion proteins represent a major step forward towards the development 
of antigen specific therapy for clinical use.  All know previous therapeutics in a clinical setting 
do not treat myocarditis with antigen specific inhibition of the immune system.  For some 
patients supportive therapies that manage cardiac load are enough for a recovery, however, other 
patients spiral into progressive cardiac inflammation that culminates in cardiomyopathy and 
heart failure.  Multiple types of clinical myocarditis including giant cell myocarditis and 
eosinophilic myocarditis have especially grim prognoses but do respond to general autoimmune 
inhibitors such as prednisone [28, 36, 37].  The response to prednisone is promising, and 
suggests if more precise and effective immuno-modulatory therapeutics, such GMCSF-Myosin 
fusion proteins, were developed for clinical application they could have a major positive impact 
on treatment and survival rates.  In addition, multiple clinical trials studying the effects of 
immunosuppression on myocarditis found increased HLA expression, anti-cardiac antibodies, 
and presence of T cells were the best indicators for a positive response to immune suppression 
therapy [27, 39, 40].  These studies highlight the need for a more effective treatment with 





T cells.  Permanent inhibition of auto-reactive cardiac specific CD4
+
T 
cells would prevent future cardiac insults from reigniting these antigen specific lymphocytes that 





















4.5 EAM on the C57BL/6 background 
Previous experiments using whole cardiac myosin emulsified in CFA have found wild 
type C57BL/6 to be resistant to EAM [49].  A bioinformatics approach was used to identify 
specific epitopes from the cardiac myosin heavy chain that may have affinity for H2-I-A
b
 using 
the website: http://tools.immuneepitope.org/mhcii/ [110, 111].  To confirm the accuracy of the 
algorithm the murine cardiac myosin heavy chain was tested against H2-I-A
d
 and myelin 
oligodendrocyte glycoprotein was tested against H2-I-A
b
.  These tests were conducted due to 
known peptide sequences, myosin 614-629 and MOG 35-55, that are capable of inducing EAM 
and EAE, respectively.  The algorithm successfully identified the peptide sequences already 
known to cause EAM and EAE and therefore was used to predict a peptide antigen from the 
cardiac myosin heavy chain capable of causing EAM in C57BL/6 (H2-I-A
b
) mice.    
 
The algorithm predicted myosin 718-736, a peptide derived from the alpha cardiac 
myosin heavy chain, would have high affinity for mice expressing the H2-I-A
b
 allele.  Using 
specific epitopes versus and an entire protein increases the likelihood of expanding CD4
+
 T cells 
that recognize a particular antigen.  The disadvantage of this approach is if the peptide included 
is not a major antigen, autoimmune disease is less likely compared to using a total protein.  To 
further increase the chance of myosin 718-736 induced EAM in mice on the C57BL/6 
background IFN-γ receptor deficient mice were selected.  Enhanced EAE has been observed in 
IFN-γ 
-/-
 mice and B cell deficient mice on the C57BL/6 background [52, 53].  Additionally 
enhanced EAM has been observed in Ifng 
-/-
 or Ifngr1 
-/-
 mice on the BALB/c background [61, 
79-81].  Therefore in addition to testing the theoretical EAM peptide (myosin 718-736) in wild 
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type C57BL/6 mice, Ifngr1 
-/-
 mice and B cell deficient mice were used to explore EAM on the 
C57BL/6 background.  
It was found myosin 718-736 is a potent antigen capable of inducing severe myocarditis 
in mice on the C57BL/6 background.  Figure 3.20 demonstrates Myosin 718-736 can induce 
EAM in both genders of Ifngr1 
-/-
 mice.  Figure 3.22 shows myosin 721-735 can induce EAM in 
male but not female Ifngr1 
-/-
mice.  The loss of pathogenicity between myosin 718-735 and 
myosin 721-735 is reflected in figure 3.23 where myosin 721-735 is only able to activate a 
subset of Myosin 718-736 T cells from primed splenocytes compared to myosin 718-736.  It is 
possible multiple epitopes are presented from a single peptide due to different anchor residues 
making contact with the variable regions of the MHC II pocket.  Having a shorter peptide such as 
myosin 721-735 could possible reduce the number of anchor residues.  Another theory for the 
loss of pathogenicity between the two peptides could relate to inefficient loading on MHC II due 
to the shorter length.   
In an effort to explore the mechanisms responsible for EAM in Ifngr1 
-/-
 mice, a study 
was conducted with iNOS2 
-/-
 mice. Previous experiments have suggested IFN-γ dependent nitric 
oxide is responsible for increased apoptosis of activated antigen specific T cells in experimental 
autoimmune disease in C57BL/6 mice [80].  However other studies have shown inhibition of 
nitric oxide in BALB/c mice did not reproduce the severe EAM observed in IFN-γ deficient mice 
on this strain [82].  In figure 3.24, iNOS2
-/-
 mice on the C57BL/6 background failed to develop 
EAM when challenged with myosin 718-736.  It is therefore likely the severe EAM in Ifngr1 
-/-
 
mice on the C57BL/6 background is not solely due to nitric oxide.  Future experiments  are need 
to confirm the exact signaling molecules downstream from IFN-γ, responsible for regulating 
apoptosis of myosin 718-736 specific T cells and thus controlling EAM in C57BL/6 mice. 
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Although EAM was shown to be possible in only one previously resistant H2 haplotype, 
it does raise the question of the incidence of auto reactive T cells in the human population.  In 
C57BL/6 mice auto reactive T cells that recognize epitopes derived from cardiac myosin do 
exists in the periphery.  The major reason for C57BL/6 wild type EAM resistance is probably 
due to antigen specific T regulatory cells and other unknown variables.  Previous research has 
indicated cardiac myosin maybe weakly expressed in the thymus where elimination of self-
reactive T cells occurs [14].  More research is needed to conclusively state cardiac myosin is 
indeed weakly expressed in the thymus.  However if cardiac antigens are under expressed in the 
human thymus, a significant portion of the population may possess cardiac auto reactive T cells.  

















New therapies are urgently needed to treat autoimmune myocarditis and prevent 
progression to dilated cardiomyopathy and heart failure.  Current therapies for managing 
autoimmune myocarditis are limited to global immunosuppressive treatment and supportive 
medication for cardiac output.  Certain types of myocarditis including giant cell myocarditis and 
eosinophilic myocarditis have especially grim prognoses.  Multiple factors are likely responsible 
for developing clinical autoimmune myocarditis.  However cardiac auto reactive CD4
+
 T cells 
are likely a major contributing factor to autoimmune myocarditis.  Future treatments which can 
selectively manage the cardiac specific leukocytes are desperately needed for these patients.  
GMCSF-Myosin fusion proteins show promise as platform for drug development to selectively 
manage cardiac specific T cells.  If GMCSF-Myosin fusion proteins are found to operate through 
T regulatory cells capable of infectious tolerance, they have the potential to provide 
immunological memory over multiple cardiac epitopes.  While hurdles such as epitope 
identification and mechanism verification must be overcome for human application, GMCSF-
antigen fusion proteins provide a novel exciting platform for autoimmune disease therapeutic 
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